

in vivo

**International Journal of Experimental and
Clinical Pathophysiology and Drug Research**

ISSN: 0258-851X

**Volume 24
2010**

INDEX

Editorial Board

- N.J. AGNANTIS, *Department of Pathology, University of Ioannina, Ioannina, Greece*
D. ANDERSON, *Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK*
V. BARAK, *Department of Oncology, Hadassah University Hospital, Jerusalem, Israel*
M.H. BARCELLOS-HOFF, *Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA*
Y. BECKER, *Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel*
K. BEIER, *Department of Histology, University of Basel, Basel, Switzerland*
S. BEN-EFRAIM, *Department of Human Microbiology, University of Tel-Aviv, Tel-Aviv, Israel*
M. BERGQVIST, *Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden*
R. BJERKVIG, *Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway*
B. BODEY, *Department of Pathology, University of Southern California, Reseda, CA, USA*
D.A. BUTTERFIELD, *Department of Biological and Physical Chemistry, University of Kentucky, Lexington, KY, USA*
M. CARAGLIA, *Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy*
P. CHANDRA, *Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany*
J.-G. CHUNG, *Department of Medicine, China Medical College, Taichung, Taiwan, ROC*
L.A. COHEN, *Northampton, MA, USA*
A.I. CONSTANTINOU, *Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus*
J.G. CORY, *Department of Biochemistry and Molecular Biology, East Carolina University, Greenville, NC, USA*
T. DALIANIS, *Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden*
G. DELICONSTANTINOS, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*
D.T. DENHARDT, *Department of Cell Biology and Neurosciences, Rutgers University, Piscataway, NJ, USA*
W. DEN OTTER, *VUMC - Department of Urology, Amsterdam, The Netherlands*
K. DE MEIRLEIR, *Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium*
L. DE RIDDER, *Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium*
E.P. DIAMANDIS, *Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada*
T. EFFERTH, *Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany*
I. EMBER, *Department of Public Health, University of Pécs Medical School, Pécs, Hungary*
W. ENGSTRÖM, *Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden*
M. ESKELINEN, *Department of Surgery, University Hospital of Kuopio, Kuopio, Finland*
J.A. FERNANDEZ-POL, *Metalloproteomics, LLC, Chesterfield, MO, USA*
S. FERRONE, *Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA*
G. FIORENTINI, *Department of Oncology, San Giuseppe – Antica Sede Hospital, Empoli (FI), Italy*
P.B. FISHER, *Virginia Commonwealth University, School of Medicine, Richmond, VA, USA*
I. FREITAS, *Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy*
M. FRIEDRICH, *Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany*
R.E. FRIEDRICH, *Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany*
R. GANAPATHI, *Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA*
Z. GATALICA, *Department of Pathology and Creighton Medical Laboratories, Creighton University Medical Center, Omaha, NE, USA*
D.H. GILDEN, *Department of Neurology, University of Colorado Denver School of Medicine, Aurora, CO, USA*
G. GITSCH, *Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany*
J.S. GREENBERGER, *Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA*

- J.W. GREINER**, *National Cancer Institute, NIH, Bethesda, MD, USA*
- D.S. GRIDLEY**, *Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA*
- C.J. GRUBBS**, *Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA*
- F. GUADAGNI**, *IRCCS San Raffaele, Rome, Italy*
- F. HALBERG**, *Chronobiology Laboratories, University of Minnesota, Minneapolis, MN, USA*
- R.R. HARDY**, *Fox Chase Cancer Center, Philadelphia, PA, USA*
- J. HAU**, *Department of Comparative Medicine, University of Copenhagen, Denmark*
- M. HAUER-JENSEN**, *Arkansas Cancer Research Center, University of Arkansas Medical Sciences, Little Rock, AR, USA*
- G.H. HEPPNER**, *Department of Immunology, Michigan Cancer Foundation, Detroit, MI, USA*
- K. HIBI**, *Department of Surgery, Showa University Fujigaoka Hospital, Yokohama, Japan*
- S.A. IMAM**, *Huntington Medical Research Institutes, Gene Therapy Program, Pasadena, CA, USA*
- C.G. IOANNIDES**, *Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- J.R. IZBICKI**, *Chirurgische Universitätsklinik, Universitätskrankenhaus Hamburg, Germany*
- K.S. JEONG**, *Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, S. Korea*
- M. KOUTSILIERIS**, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*
- G.R.F. KRUEGER**, *Department of Anatomy II, Center for Anatomy, The University of Cologne Medical School, Cologne, Germany*
- B. KRUSLIN**, *Department of Pathology, Ljudevit Jurak University, Sestre milosrdnice University Hospital, Zagreb, Croatia*
- S.A. LAMPRECHT**, *Division of Clinical Biochemistry, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel*
- G. LANDBERG**, *Department of Laboratory Medicine, Lund University, Lund, Sweden*
- I. LELONG-REBEL**, *Lab. de Biophotonique et Pharmacologie, Université de Strasbourg, Illkirch, France*
- J. LEROY**, *IRCAD, University of Strasbourg, France*
- B. LÉYLAND-JONES**, *Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA*
- W. LICHTENEGGER**, *Charité Campus Virchow-Klinikum, Berlin, Germany*
- P. MADARNAS**, *Department of Pathology, University of Sherbrooke, Québec, Canada*
- H. MAEDA**, *Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan*
- M. MAREEL**, *Laboratory of Experimental Cancerology, State University, Ghent, Belgium*
- G. MARTORANA**, *Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy*
- D.P. MIKHAILIDIS**, *Department of Chemical Pathology, The Royal Free Hospital, London, UK*
- H.C. MORSE III**, *Laboratory of Immunopathology, NIH, Rockville, MD, USA*
- N. MOTOHASHI**, *Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, Japan*
- R.M. NAGLER**, *Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel*
- R. NARAYANAN**, *Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA*
- K. NILSSON**, *Tumor Biology Laboratory, Department of Pathology, University Hospital, Uppsala, Sweden*
- K.R. NORUM**, *Institute for Nutrition Research, University of Oslo, Oslo, Norway*
- R.F. NOVAK**, *Division of Clinical Pharmacology and Toxicology, Wayne State University, School of Medicine, Detroit, MI, USA*
- J. O'KELLY**, *Division of Hematology-Oncology, Cedar Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA*
- M. PAGÉ**, *Département de Biologie, Division de Biochimie, Université Laval, Québec, Canada*
- P. PANTAZIS**, *Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA*

- M.-F. POUPON**, *Institut Curie, Section de Recherche, Paris, France*
- F.M. ROBERTSON**, *Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- D. RUBELLO**, *Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy*
- C.A. RUBIO**, *Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden*
- G.R. RUTTEMAN**, *Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands*
- H. SAKAGAMI**, *Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan*
- G. SAVA**, *Institutes of Biological Research, Fondazione Callerio-Onlus, Trieste, Italy*
- D. SCHIFFER**, *Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy*
- L.D. SHULTZ**, *The Jackson Laboratory, Bar Harbor, ME, USA*
- G. SICA**, *Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy*
- R.M. SNAPKA**, *Department of Radiology, The Ohio State University, Columbus, OH, USA*
- G.-I. SOMA**, *Institutes for Health Sciences, Tokushima Bunri University, Tokushima, Japan*
- T.A. SPRINGER**, *Department of Pathology, Harvard Medical School, Boston, MA, USA*
- T. TAKAHASHI**, *Aichi Cancer Center, Nagoya, Japan*
- N. TANAKA**, *Department of Animal Pharmaceutical Science, Chiba Institute of Science, Chiba, Japan*
- H. TAPIERO**, *Biomedicine & Pharmacotherapy, ICIG, Hopital Paul-Brousse, Villejuif, France*
- K.D. TEW**, *Department of Pharmacology, Medical University of South Carolina, Charleston, SC, USA*
- G.C. TORRE**, *Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy*
- B. TRIBUKAIT**, *Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden*
- J. VADGAMA**, *Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA*
- N. WATANABE**, *Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan*
- W. WEBER**, *Clinical Cancer Etiology Unit, Basel, Switzerland*
- L.M. WEINER**, *Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA*
- J.A. WERNER**, *Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany*
- S. YLÄ-HERTTUALA**, *Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland*
- H. YOSHIDA**, *Department of Pathology, Kagoshima University, Kagoshima, Japan*

Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 24, 2010.

- Academy of Finland, Helsinki, Finland
ACM Pharmaceutical Co., Ltd, Tokyo, Japan
Association Française d'Urologie (AFU), Paris, France
Associazione Sarda per la Ricerca in Oncologia Ginecologica-ONLUS, Italy
Austrian Science Fund (FWF), Vienna, Austria
- Blum Kovler Foundation, Chicago, IL, U.S.A.
- Cancer Federation, Banning, CA, U.S.A.
Cancer Foundation in Gävle, Sweden
Charles University in Prague, Faculty of Medicine in Pilsen, Czech Republic
China Medical University, Taichung, Taiwan, R.O.C.
Chulabhorn Research Institute, Thailand
Coleman Foundation, Chicago, IL, U.S.A.
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil
CPER, Crédits du Conseil Régional D'Auvergne/Axe Nutrition et Cancer, Clermont-Ferrand, France
- Danish Data Protection Agency, Denmark
Danish Medical Research Council, Copenhagen, Denmark
Danish National Board of Health, Denmark
Danish Research Council
Deutscher Akademischer Austausch Dienst (DAAD), Bonn, Denmark
Dominicks Campaign for Breast Cancer Awareness, U.S.A.
- European Commission, Brussels, Belgium
- Fasel S.r.l., Bologna, Italy
Financiadora de Estudos e Projetos (FINEP), Brazil
Flanders Research Foundation (FWO), Brussels, Belgium
Foundation for Polish Science, Warsaw, Poland
Friedrich Baur Institute Munich, Germany
Fujii Memorial Osaka Foundation for Promotion of Fundamental Medical Research, Osaka, Japan
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Brazil
Fundação de Amparo à Pesquisa do Estado do Pará (FAPESPA), Belem, Brazil
Fundação de Amparo e Desenvolvimento da Pesquisa (FADESP), Brazil
- Fundación para la Investigación con Celulas Medie Uterinas, Spain
- Gillson Logenbaugh Foundation, Houston, TX, U.S.A.
Greek Scholarships Foundation (IKY), Athens, Greek
- Hellenic Cardiological Society and the Cardiovascular Research Institute, Ioannina and Athens, Greece
Herbert C. Wenske Foundation, U.S.A.
- Istanbul University Research Foundation, Turkey
Istanbul University, Turkey
- Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
- Karolinska Institute, Stockholm, Sweden
Kuopio University Hospital, Finland
- Lawn Manor Beth Jacob Hebrew Congregation, U.S.A.
Lobund Institute Endowment, University of Notre Dame, IN, U.S.A.
Loma Linda University Medical Center (LLUMC), Department of Radiation Medicine, Loma Linda, CA, U.S.A.
Ludwig Maximilians University Munich, Germany
- Max Goldenberg Foundation, U.S.A.
Meikai University, Chiba, Japan
Ministry of Education, Science, Sports and Culture of Japan
Ministry of Health, Czech Republic
- National Aeronautics and Space Administration (NASA), Washington, DC, U.S.A.
National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, U.S.A.
National Center for Research Resources, National Institutes of Health (NIH), Bethesda, MD, U.S.A.
National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, U.S.A.
National High Technology Research and Development Program of China
National Institute for Diabetes, Digestive and Kidney (NIDDK), National Institutes of Health (NIH), Bethesda, MD, U.S.A.
National Institutes of Health (NIH), Bethesda, MD, U.S.A.

National Key Basic Research Program of China
National Medical Technology Testbed (NMTB), Loma Linda
University Medical Center (LLUMC), Loma Linda, CA,
U.S.A.
National Natural Sciences Foundation of China
Norwegian Data Inspectorate, Oslo, Norway

Osaka Community Foundation, Osaka, Japan

Paavo Koistinen Foundation, Finland
Provincial Archives of Sealand, Denmark

Regional Committees for Medical Research Ethics, Norway
Retirement Research Foundation, Chicago, IL, U.S.A.
Royal Danish Archives, Copenhagen, Denmark
Rural Development Administration, Republic of Korea

Safeway Campaign for Breast Cancer Awareness, U.S.A.
Sapporo Medical Association, Hokkaido, Japan
Scully Trust, U.S.A.

Social and Health Directorate, Oslo, Norway
Soluscience S.A., Clermont-Ferrand, France
Sonoko Morimoto Foundation of the Kansai Medical
University Alumni Association, Osaka, Japan
Sternfeld Family Foundation, U.S.A.
Suzuken Memorial Foundation, Japan
Swedish Research Council, Stockholm, Sweden

U.S. Department of Veterans Affairs, Washington, DC, U.S.A.
United States Soyboard
Universidad Autónoma del Estado de México, México
University College Antwerp, Belgium
University of Oslo, Faculty Division of Aker University
Hospital, Norway

Vanjan Inc., Houston, TX, U.S.A.
Venex Co., Ltd., Kanagawa, Japan

Wilhelm Sander Stiftung, München, Germany

Contents, Volume 24, 2010

Number 1

Experimental Studies

Effectiveness of Combined Modality Radiotherapy of Orthotopic Human Squamous Cell Carcinomas in Nu/Nu Mice Using Cetuximab, Tirapazamine and MnSOD-Plasmid Liposome Gene Therapy. M.W. EPPERLY, S.Y. LAI, A.J. KANAI, N. MASON, B. LOPRESI, T. DIXON, D. FRANICOLA, Y. NIU, W.R. WILSON, J.S. GREENBERGER (<i>Pittsburgh, PA, USA; Auckland, New Zealand</i>)	1
Screening of Antimicrobial Agents for <i>In Vitro</i> Radiation Protection and Mitigation Capacity, Including those Used in Supportive Care Regimens for Bone Marrow Transplant Recipients. M.W. EPPERLY, D. FRANICOLA, D. SHIELDS, J.-C. RWIGEMA, B. STONE, X. ZHANG, W. MCBRIDE, G. GEORGES, P. WIPF, J.S. GREENBERGER (<i>Pittsburgh, PA; Los Angeles, CA; Seattle, WA, USA</i>)	9
Rational Targeting in Acute Promyelocytic Leukemia. N.A. PAPANIKOLAOU (<i>Thessaloniki, Greece; New York, NY, USA</i>).....	21
Effect of Contact with Titanium Alloys on the Proliferation of Mouse Osteoblastic Cells in Culture. H. ONUKI, H. SAKAGAMI, M. KOBAYASHI, Y. HIBINO, Y. YOKOTE, H. NAKAJIMA, J. SHIMADA (<i>Saitama, Japan</i>)	29
Hormetic Response of Cultured Normal and Tumor Cells to 2-Aminotropone Derivatives. H. WAKABAYASHI, T. NARITA, A. SUGA, H. SAKAGAMI (<i>Saitama, Japan</i>).....	39
CD40L-Transfected Myeloma Cells Transfer Prolonged Immunity <i>In Vivo</i> . Y. KIM, J.W. STREHL, E. SIEVERS, M. GORSCHLÜTER, P. BROSSART, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany</i>).....	45
Resveratrol Activation of Nitric Oxide Synthase in Rabbit Brain Synaptosomes: Singlet Oxygen (1O_2) Formation as a Causative Factor of Neurotoxicity. S. FOTIOU, D. FOTIOU, A. ALAMANOU, G. DELICONSTANTINOS (<i>Athens, Greece</i>).....	49
Inhibition of Prostaglandin E2 Production by Flavone and its Related Compounds. T. KANEKO, H. CHIBA, N. HORIE, T. KATO, M. KOBAYASHI, K. HASHIMOTO, K. KUSAMA, H. SAKAGAMI (<i>Tokyo; Saitama, Japan</i>)	55
Comparison of the Effect of Orally Administered Soluble β -(1-3),(1-6)-D-Glucan and of G-CSF on the Recovery of Murine Hematopoiesis. U. HARNACK, K. ECKERT, I. FICHTNER, G. PECHER (<i>Berlin, Germany</i>).....	59
Comparison of Lipid Profiles in Relation to APOB EcoRI Polymorphism in Obese Children with Hyperlipidemia. O. TİMİRCİ, F. DARENDELİLER, F. BAS, E.H. ARZU, Z. UMİT, T. İSBİR (<i>Istanbul, Turkey</i>)	65
CYP17 (T-34C) and CYP19 (Trp39Arg) Polymorphisms and their Cooperative Effects on Breast Cancer Susceptibility. B.M. TÜZÜNER, T. ÖZTÜRK, H.I. KISAKESEN, Ş. İLVAN, C. ZERRİN, O. ÖZTÜRK, T. İSBİR (<i>Istanbul, Turkey</i>)	71

Relationship between Psychoncology and Psychoneuroendocrinoimmunology (PNEI): Enhanced T-Regulatory Lymphocyte Activity in Cancer Patients with Self-punishment, Evaluated by Rorschach Test. G. MESSINA, P. LISSONI, E. BARTOLACELLI, L. MAGOTTI, M. CLERICI, P. MARCHIORI, E. COLOMBO (<i>Milan, Italy</i>).....	75
<i>Clinical Studies</i>	
Treatment of Peritoneal Carcinomatosis from Colonic Cancer by Cytoreduction, Peritonectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Experience of Ten Years. M. VAIRA, T. CIOPPA, S. D' AMICO, G. DE MARCO, M. D' ALESSANDRO, G. FIORENTINI, M. DE SIMONE (<i>Empoli, Florence, Italy</i>)	79
Familial Chronic Lymphocytic Leukemia in Norway and Denmark. Comments on Pleiotropy and Birth Order. V. JØNSSON, G.E. TJØNNFJORD, T.B. JOHANNESSEN, B. LY, J.H. OLSEN, M. YUILLE (<i>Oslo, Norway; Copenhagen, Denmark; Manchester, UK</i>)	85
* Review: Radioguided Surgery and Systemic Radionuclide Therapy of Neuroendocrine Tumours. M. HODOLIČ, J. FETTICH, M.C. MARZOLA, E. TONINI, A. AL-NAHHAS, D. RUBELLO (<i>Ljubljana, Slovenia; Rovigo, Italy; London, UK</i>).....	97
CX32 and CX43 Expression to Cytoplasmic Pattern During Colorectal Carcinogenesis. L. KANCZUGA-KODA, M. KODA, S. SULKOWSKI, A. WINCEWICZ, B. ZALEWSKI, M. SULKOWSKA (<i>Bialystok, Poland</i>)	101
Synchronous Presentation of GISTs and Other Primary Neoplasms: A Single Center Experience. N. ARNOGIANNAKI, I. MARTZOUKOU, P. KOUNTOURAKIS, E. DIMITRIADIS, A. PAPATHANASAKI, E. NASTOULIS, M. GAZALIDOU, A. FIDA, N. APOSTOLIKAS, N.J. AGNANTIS (<i>Athens; Ioannina, Greece; Houston, TX, USA</i>)	109
Immune Response Parameters During Labor and Early Neonatal Life. E. PROTONOTARIOU, C. CHRELIAS, D. KASSANOS, H. KAPSAMBELI, E. TRAKAKIS, A. SARANDAKOU (<i>Thessaloniki; Athens, Greece</i>)	117
* Review (page 97)	

Number 2

Experimental Studies

Twice-weekly Intravenous Treatment of Pancreatic Cancer with Atrial Natriuretic Peptide and Vessel Dilator. A. LENZ, Y. SUN, E.J. EICHELBAUM, W.P. SKELTON IV, G. PI, D.L. VESELY (<i>Tampa, FL, USA</i>)	125
Effects of Voluntarily-ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behaviour in Permanently Catheterised Rats. R. GOLDKUHL, J. HAU, K.S.P. ABELSON (<i>Uppsala, Sweden; Copenhagen, Denmark</i>).....	131
Renal Uptakes of ^{99m} Tc-MAG3, ^{99m} Tc-DTPA, and ^{99m} Tc-DMSA in Rabbits with Unilateral Ureteral Obstruction. W.G. LEE, J.-H. KIM, J.M. KIM, K.M. SHIM, S.S. KANG, H.I. CHAE, S.H. CHOI (<i>Chungbuk; Nambu; Chonnam; Juseong, Republic of Korea</i>).....	137

Modulation of Aged Murine T Lymphocytes <i>In Vivo</i> by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, A. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (<i>Los Angeles, CA, USA</i>)..	141
Chronic Hind Limb Ischemia Reduces Myocardial Ischemia-Reperfusion Injury in the Rabbit Heart by Promoting Coronary Angiogenesis/Arteriogenesis. V.C. VARNAVAS, K.I. PARASKEVAS, E.K. ILIODROMITIS, A. ZOGA, I. GLAVA, L. KAKLAMANIS, J. SPARTINOS, T. LYRAS, D.T. KREMASTINOS, D.P. MIKHAILIDIS, Z.S. KYRIAKIDES (<i>Athens, Greece; London, UK</i>)	147
Carbon Nanotubes Induce Granulomas but Not Mesotheliomas. C. VARGA, K. SZENDI (<i>Pécs, Hungary</i>)..	153
Oxytocin Both Increases Proliferative Response of Peripheral Blood Lymphomonocytes to Phytohemagglutinin and Reverses Immunosuppressive Estrogen Activity. A. MACCIÒ, C. MADEDDU, P. CHESSA, F. PANZONE, P. LISSONI, G. MANTOVANI (<i>Carbonia; Cagliari; Monza, Italy</i>)	157
Experimental Xenotransplantation of Antlerogenic Cells into Mandibular Bone Lesions in Rabbits: Two-year Follow-up. M. CEGIELSKI, W. DZIEWISZEK, M. ZABEL, P. DZIĘGIEL, J. KURYSZKO, I. IŻYKOWSKA, M. ZATOŃSKI, M. BOCHNIA (<i>Wroclaw; Poznan, Poland</i>)	165
17 β -Estradiol Acting as an Electron Mediator: Experiments <i>In Vitro</i> . N. GETOFF, H. SCHITTL, M. GERSCHPACHER, J. HARTMANN, J.C. HUBER, R.-M. QUINT (<i>Vienna, Austria</i>).....	173
Association between <i>CDKN1A</i> Ser31Arg and C20T Gene Polymorphisms and Colorectal Cancer Risk and Prognosis. C. CACINA, İ. YAYLİM-ERALTAN, S. ARİKAN, E.K. SAGLAM, U. ZEYBEK, T. İSBİR (<i>Istanbul, Turkey</i>).....	179
<i>Clinical Studies</i>	
Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDAL, K.-M. MYHR, H.I. NYLAND (<i>Bergen, Norway</i>).....	185
Effect of Atorvastatin on Cellular Adhesion Molecules on Leukocytes in Patients with Normocholesterolemic Coronary Artery Disease. T. WALTER, T. SUSELBECK, M. BORGGREFE, S. SWOBODA, H.M. HOFFMEISTER, C.-E. DEMPFLER (<i>Mannheim; Solingen; Heidelberg, Germany</i>)	189
Spirometric Reference Values in Greek Children and Adolescents. S. ALEXANDRAKI, M. KOUTSILIERIS, N. SIAFAKAS, C. KATSARDIS (<i>Athens; Heraklion, Greece</i>)	195
Development of fMRI Tests for Children with Central Auditory Processing Disorders. S. BARTELFRIEDRICH, Y. BROECKER, M. KNOERGEN, S. KOESLING (<i>Halle/Saale, Germany</i>)	201
Multiple Distant Metastases of Hepatocellular Carcinoma to the Oral Cavity. R.E. FRIEDRICH, J. ZUSTIN (<i>Hamburg, Germany</i>)	211
Iterative Surgical Resection of a Recurrent Gallbladder Carcinoma with Long-term Survival: Report of a Case. S. SCARINGI, G. NESI, T. BARGELLINI, G. BATIGNANI, F. TONELLI (<i>Florence, Italy</i>).....	215
The Use of the Veress Needle to Drain Mammary Periprosthetic Fluid. M. MAZZOCCHI, L.A. DESSY, F. MARCHETTI, F. MARCHETTI, B. CARLESIMO (<i>Perugia; Rome, Italy</i>)	219
The Role of Carbon Dioxide Therapy in the Treatment of Chronic Wounds. C. BRANDI, L. GRIMALDI, G. NISI, A. BRAFA, A. CAMPA, M. CALABRÒ, M. CAMPANA, C. D' ANIELLO (<i>Siena, Italy</i>)	223
Impact of Adjuvant Chemo- and Radiotherapy on the Cellular Immune System of Breast Cancer Patients. T. MELLIOS, H. LIOE KO, J. BEUTH (<i>Köln, Germany</i>)	227

Complete Recovery from Undertreated Wernicke-Korsakoff Syndrome Following Aggressive Thiamine Treatment. T. PAPARRIGOPOULOS, E. TZAVELLAS, D. KARAIKOS, A. KOUZOUPIS, I. LIAPPAS (Athens, Greece).....	231
Dual-headed Coincidence PET vs. Dedicated PET/CT in the Evaluation of Thoracic Malignancies. S. BERGSTRÖM, G. HOLGERSSON, J.-E. BERGQVIST, M. BERGQVIST, S. EKMAN, M. STENSTRÖM (Gävle; Uppsala; Falun, Sweden)	235
Synchronization of Cortisol Circadian Rhythm by the Pineal Hormone Melatonin in Untreatable Metastatic Solid Tumor Patients and its Possible Prognostic Significance on Tumor Progression. F. BRIVIO, L. FUMAGALLI, G. FUMAGALLI, S. PESCIA, R. BRIVIO, G. DI FEDE, F. ROVELLI, P. LISSONI (Milan; Monza, Italy).....	239
Association of CCL2 and CCR2 Gene Variants with Endometrial Cancer in Turkish Women. R. ATTAR, B. AGACHAN, S.B. KURAN, C. CACINA, S. SOZEN, L.M. YURDUM, E. ATTAR, T. ISBIR (Istanbul, Turkey).....	243

Number 3

Experimental Studies

Pharmacological Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (Bethesda, MD; Notre Dame, IN, USA)	249
A Non-traumatic <i>Staphylococcus aureus</i> Osteomyelitis Model in Pigs. H.E. JENSEN, O.L. NIELSEN, J.S. AGERHOLM, T. IBURG, L.K. JOHANSEN, E. JOHANNESSON, M. MØLLER, L. JAHN, L. MUNK, B. AALBÆK, P.S. LEIFSSON (Frederiksberg C, Denmark)	257
Pretreatment with Tetrandrine Has Protective Effects against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNNA, G. GALMOZZI, G. ROSSONI (Milan, Italy)	265
A Possible Key Molecule for the Invasion of the <i>Plasmodium berghei</i> Ookinetes into the Midgut Epithelium of <i>Anopheles gambiae</i> Mosquitoes. D.N. TOUBARRO, D. RALHA, S. CARVALHO, A.M. TOMÁS, A.P.G. ALMEIDA (Lisboa; Porto, Portugal).....	271
Chromosome X Aneuploidy in Brazilian Schizophrenic Patients. L.S. DE MORAES, A.S. KHAYAT, P.D. DE LIMA, E.M. LIMA, G.R. PINTO, M.F. LEAL, M. DE ARRUDA CARDOSO SMITH, R.R. BURBANO (Belém, PA; Parnaíba, PI; São Paulo, Brazil)	281
Gypenosides Causes DNA Damage and Inhibits Expression of DNA Repair Genes of Human Oral Cancer SAS Cells. K.-W. LU, J.-C. CHEN, T.-Y. LAI, J.-S. YANG, S.-W. WENG, Y.-S. MA, N.-Y. TANG, P.-J. LU, J.-R. WENG, J.-G. CHUNG (Taichung; Tainan, Taiwan, ROC)	287
Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in the Follicular Fluid of Patients with Polycystic Ovaries Undergoing <i>In Vitro</i> Fertilisation. S. BAKA, K. ZOURLA, E. KOUSKOUNI, E. MAKRAKIS, S. DEMERIDOU, D. TZANAKAKI, D. HASSIAKOS, G. CREATSAS (Athens, Greece).....	293

Genetic Variants of Vascular Endothelial Growth Factor and Risk for the Development of Endometriosis. R. ATTAR, B. AGACHAN, S.B. KURAN, B. TOPTAS, I. YAYLIM ERALTAN, E. ATTAR, T. ISBIR (<i>Istanbul, Turkey</i>)	297
Feeding Purified Glycerol from Biodiesel to CBA/CA Mice: Effects on <i>Gadd45a</i> and <i>Nfκb1</i> Expressions. E. SZELE, K. GOMBOS, A. KOVÁCS, I. EMBER (<i>Pécs; Budapest, Hungary</i>)	303
<i>Clinical Studies</i>	
Milroy' s Primary Congenital Lymphedema in a Male Infant and Review of the Literature. S. KITSIOU-TZELI, C. VRETTOU, E. LEZE, P. MAKRYTHANASIS, E. KANAVAKIS, P. WILLEMS (<i>Athens, Greece; Geneva, Switzerland; Antwerp, Belgium</i>)	309
Expression Profiling of Cell Cycle Regulatory Proteins in Oropharyngeal Carcinomas Using Tissue Microarrays. D.A. RIBEIRO, F.D. NASCIMENTO, A.C.C. FRACALOSSO, T.S. GOMES, C.T.F. OSHIMA, M.F. FRANCO (<i>São Paulo, Brazil</i>)	315
Periampullary Gangliocytic Paraganglioma: a Case Report. K. VON LOGA, A. KΦNIG, J. ZUSTIN (<i>Hamburg, Germany</i>)	321
Hypoxemia and Hypoventilation Syndrome Improvement after Laparoscopic Bariatric Surgery in Patients with Morbid Obesity. F. LUMACHI, B. MARZANO, G. FANTI, S.M.M. BASSO, F. MAZZA, G.B. CHIARA (<i>Padova; Pordenone, Italy</i>).....	325
Alteration of Biological Markers in Alcohol-dependent Individuals without Liver Disease during the Detoxification Therapy. S. CHATZIPANAGIOTOU, M. KALYKAKI, E. TZAVELLAS, D. KARAIKOS, T. PAPARRIGOPOULOS, A. LIAPPAS, C. NICOLAOU, M. MICHALOPOULOU, M. ZOGA, F. BOUFIDOU, I. LIAPPAS (<i>Athens; Greece; Preston, UK</i>)	329
The Role of Fine-needle Aspiration Performed with Liquid-based Cytology in the Surgical Management of Thyroid Lesions. G. ARDITO, E.D. ROSSI, L. REVELLI, F. MOSCHELLA, E. GIUSTOZZI, G. FADDA, M.C. MARZOLA, D. RUBELLO (<i>Rome; Rovigo, Italy</i>).....	333
Umbilical Cord Blood Donation during Caesarean Section Does not Lead to Increased Maternal Blood Loss. I. ZAISS, S. KEHL, E. PETRI, K. HELBIG, M. SÜTTERLIN, J. SIEMER (<i>Mannheim, Germany</i>)	339
ABSTRACTS OF THE 3rd SWEDISH-HELLENIC LIFE SCIENCES RESEARCH CONFERENCE, Athens, March 25-27, 2010.....	341

Number 4

Experimental Studies

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-induced Delay in Bone Wound Healing in a Novel Murine Model. A. GOKHALE, J.-C. RWIGEMA, M.W. EPPERLY, J. GLOWACKI, H. WANG, P. WIPF, J.P. GOFF, T. DIXON, K. PATRENE, J.S. GREENBERGER (<i>Pittsburgh, PA; Boston, MA, USA</i>) ...	377
Diindolylmethane (DIM) Spontaneously Forms from Indole-3-carbinol (I3C) During Cell Culture Experiments. H.L. BRADLOW, M.A. ZELIGS (<i>Hackensack, NJ; Boulder, CO, USA</i>)	387

Soy Phytoestrogens Modify DNA Methylation of <i>GSTP1</i> , <i>RASSF1A</i> , <i>EPHB2</i> and <i>BRCA1</i> Promoter in Prostate Cancer Cells. A. VARDI, R. BOSVIEL, N. RABIAU, M. ADJAKLY, S. SATHI, P. DECHELOTTE, J.-P. BOITEUX, L. FONTANA, Y.-J. BIGNON, L. GUY, D.J. BERNARD-GALLON (Clermont-Ferrand; Saint Beauzire, France).....	393
Effect of Curcumin and Meriva on the Lung Metastasis of Murine Mammary Gland Adenocarcinoma. A. IBRAHIM, A. EL-MELIGY, H. FETAIH, A. DESSOUKI, G. STOICA, R. BARHOUMI (Ismailia, Egypt; College Station, TX, USA)	401
* Review: Phenothiazines, Bacterial Efflux Pumps and Targeting the Macrophage for Enhanced Killing of Intracellular XDR TB. L. AMARAL, A. MARTINS, J. MOLNAR, J.E. KRISTIANSEN, M. MARTINS, M. VIVEIROS, L. RODRIGUES, G. SPENGLER, I. COUTO, J. RAMOS, S. DASTIDAR, S. FANNING, M. MCCUSKER, J.-M. PAGES (Lisbon, Portugal; Szeged, Hungary; Kolkata, India; Dublin, Ireland; Marseille, France).....	409
Gene Expression Analysis of Oxidative Stress and Apoptosis in Proton-irradiated Rat Retina. X.W. MAO, L.M. GREEN, T. MEKONNEN, N. LINDSEY, D.S. GRIDLEY (Loma Linda, CA, USA).....	425
An Adult Myometrial Pluripotential Precursor that Promotes Healing of Damaged Muscular Tissues. B.G. GÁLVEZ, N.S. MARTÍN, P. SALAMA-COHEN, J.J. LAZCANO, M.J. CORONADO, M.L. LAMELAS, A. ÁLVAREZ-BARRIENTES, N. EIRÓ, F. VIZOSO, C. RODRÍGUEZ (Gijón, Spain).....	431
A Two-dimensional Proteomic Profile of <i>Tetrahymena thermophila</i> Whole Cell Lysate. A.G. XANTHOPOULOU, D. ANAGNOSTOPOULOS, K. VOUGAS, A.K. ANAGNOSTOPOULOS, A. ALEXANDRIDOU, G. SPYROU, A. SIAFAKA-KAPADAI, G.TH. TSANGARIS (Athens, Greece)	443
* Review: <i>In Vivo</i> Research Using Early Life Stage Models. R. SEABRA, N. BHOGAL (Nottingham, UK)	457
Effects of Fetal Exposure to 4- <i>n</i> -Octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (Kagoshima, Japan)	463
A Possible Mechanism for Altered Immune Response in the Elderly. G. MAZZOCCOLI, A. DE CATA, S. CARUGHI, A. GRECO, M. INGLESE, F. PERFETTO, R. TARQUINI (San Giovanni Rotondo; Florence, Italy).....	471
Bispecific Antisense Oligonucleotides Have Activity Comparable to Monospecifics in Inhibiting Expression of BCL-2 in LNCaP Cells. M. RUBENSTEIN, P. GUINAN (Chicago, IL, USA).....	489
Concentrations of Inflammatory Cytokines and the Outcome in ICSI Cycles. B. ASIMAKOPOULOS, C. DEMIREL, R. FELBERBAUM, S. WACZEK, N. NIKOLETTOS, F. KÖSTER, S. AL-HASANI, K. DIEDRICH (Alexandroupolis, Greece; Istanbul, Turkey; Ulm; Lübeck, Germany).....	495
Vanillin Enhances TRAIL-Induced Apoptosis in Cancer Cells through Inhibition of NF-κB Activation. K. LIRDPRAPAMONGKOL, H. SAKURAI, S. SUZUKI, K. KOIZUMI, O. PRANGSAENGTONG, A. VIRIYAROJ, S. RUCHIRAWAT, J. SVASTI, I. SAIKI (Bangkok; Nakhonnayok, Thailand; Toyama, Japan).....	501
Type of Cell Death Induced by Seven Metals in Cultured Mouse Osteoblastic Cells. R.G. CONTRERAS, J. ROGELIO S. VILCHIS, H. SAKAGAMI, YUKO NAKAMURA, YUKIO NAKAMURA, Y. HIBINO, H. NAKAJIMA, J. SHIMADA (Toluca, Mexico; Saitama, Japan).....	507

Type of Cell Death Induced by Various Metal Cations in Cultured Human Gingival Fibroblasts. R.G. CONTRERAS, H. SAKAGAMI, H. NAKAJIMA, J. SHIMADA (<i>Toluca, Estado de México, México; Saitama, Japan</i>).....	513
Quantification of Enhanced Osteoblastic Adhesion to Ultraviolet-treated Titanium Plate. R.G. CONTRERAS, K. ADACHI, Y. YOKOTE, H. SAKAGAMI, Y. HIBINO, H. NAKAJIMA, J. SHIMADA (<i>Toluca, Estado de Mexico, Mexico; Saitama, Japan</i>)	519
Reversal of Age-associated Oxidative Stress in Rats by MRN-100, a Hydro-ferrate Fluid. N.K. BADR EL-DIN, E. NOAMAN, S.M. ABDEL-FATTAH, M. GHONEUM (<i>Mansoura; Cairo, Egypt; Los Angeles, CA, USA</i>).....	525
Mutual Interaction of 17 β -Estradiol and Progesterone: Electron Emission. Free Radical Effect Studied by Experiments <i>In Vitro</i> . N. GETOFF, H. SCHITTL, J. HARTMANN, M. GERSCHPACHER, S. YING, I. DANIELOVA, J.C. HUBER (<i>Vienna, Austria</i>).....	535
Lignin-like Activity of <i>Lentinus edodes</i> Mycelia Extract (LEM). M. KAWANO, H. SAKAGAMI, K. SATOH, S. SHIODA, T. KANAMOTO, S. TERAUBU, H. NAKASHIMA, T. MAKINO (<i>Tokyo; Kanagawa, Japan</i>)	543
Short-term Pregnancy Hormone Treatment of <i>N</i> -Methyl- <i>N</i> -nitrosourea-induced Mammary Carcinogenesis in Relation to Fatty Acid Composition of Serum Phospholipids in Female Lewis Rats. Y.-C. LAI, K. HAMAZAKI, K. YOSHIZAWA, A. KAWANAKA, M. KUWATA, S. KANEMATSU, T. HAMAZAKI, H. TAKADA, A. TSUBURA (<i>Osaka; Toyama, Japan</i>).....	553
<i>Clinical Studies</i>	
Effects of Eicosapentaenoic Acid on Biochemical Failure after Radical Prostatectomy for Prostate Cancer. E. HIGASHIHARA, M. ITOMURA, T. TERACHI, T. MATSUDA, M. KAWAKITA, S. KAMEYAMA, H. FUSE, Y. CHIBA, T. HAMAZAKI, T. OKEGAWA, M. TOKUNAGA, T. MUROTA, G. KAWA, Y. FURUYA, T. AKASHI, K. HAMAZAKI, H. TAKADA (<i>Mitaka; Toyama; Isehara; Moriguchi; Kobe; Shinagawa; Sendai, Japan</i>)	561
Ameloblastoma of the Maxillary Sinus 11 Years after Extirpation of Extensive Dentigerous Cysts and Dystopic Wisdom Tooth. R.E. FRIEDRICH, J. ZUSTIN (<i>Hamburg, Germany</i>).....	567
Hypercementosis and Odontogenic Epithelial Hyperplasia Associated with a Tooth Root Remnant Mimicking a Neoplasm. A Case Report. J. ZUSTIN, R.E. FRIEDRICH (<i>Hamburg, Germany</i>)	571
Primary Amyloidosis of the Eyelid: A Case Report. A. CAGGIATI, A. CAMPANELLA, S. TENNA, A. COGLIANDRO, C. POTENZA, P. PERSICHETTI (<i>Rome, Italy</i>)	575
Absence of <i>CPI1/KIP1</i> Hypermethylation in Gastric Cancer Patients from Northern Brazil. B.D. NASCIMENTO BORGES, R.M.R. BURBANO, M.L. HARADA (<i>Belém, Pará, Brazil</i>).....	579
Tension-free Primary Closure with Autologous Platelet Gel versus Vivostat™ for the Definitive Treatment of Chronic Sacrococcygeal Pilonidal Disease. M. GIPPONI, G. REBOA, T. TESTA, G. GIANNINI, P. STRADA (<i>Genoa, Italy</i>).....	583
Efficacy of Topical Cyanoacrylates Compared to Topical Silicone Gel in the Treatment of Hypertrophic Scars. N. SCUDERI, L.A. DESSY, M. MAZZOCCHI, S. CHIUMMARIELLO, M.G. ONESTI (<i>Rome; Perugia, Italy</i>)	591

An Easy Method to Identify Parietal Cells in Gastric Biopsies. C.A. RUBIO (<i>Stockholm, Sweden</i>).....	599
AdOnco Database – Six Years’ Experience with the Documentation of Clinical and Scientific Data on Patients with Head and Neck Cancer. J. WAGENBLAST, O. ADUNKA, W. GSTÖTTNER, C. ARNOLDNER, N. RIEDL, M. DIENSTHUBER, T. STÖVER, M. HAMBEK (<i>Frankfurt am Main, Germany; Chapel Hill, NC, USA; Vienna, Austria</i>).....	603
* Reviews (pages 409, 457)	

Number 5

Experimental Studies

* Review: Colon Cancer Vaccines: An Update. E. MERIKA, M.W. SAIF, A. KATZ, K. SYRIGOS, M. MORSE (<i>London, UK; Haven, CT; Durham, NC, USA; Athens, Greece</i>).....	607
Uterus Cryopreservation in the Sheep: One Step Closer to Uterus Transplantation. R. DITTRICH, T. MALTARIS, A. MUELLER, O. STRAHL, I. HOFFMANN, M.W. BECKMANN, P.G. OPPELT (<i>Erlangen, Germany</i>).....	629
Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation. T. WALTER, K.S. REY, H.P. WENDEL, S. SZABO, T. SUSELBECK, C.-E. DEMPFLER, M. BORGGREFE, S. SWOBODA, M.E. BEYER, H.M. HOFFMEISTER (<i>Mannheim; Kirchheim; Tuebingen; Solingen, Germany</i>).....	635
The Effect of Voluntarily Ingested Buprenorphine on Rats Subjected to Surgically-induced Global Cerebral Ischaemia. O. KALLIOKOSKI, K.S.P. ABELSON, J. KOCH, A. BOSCHIAN, S.F. THORMOSE, N. FAUERBY, R.S. RASMUSSEN, F.F. JOHANSEN, J. HAU (<i>Copenhagen, Denmark; Uppsala, Sweden</i>).....	641
uPA, uPAR and TGFβ ₁ Expression during Early and Late Post Myocardial Infarction Period in Rat Myocardium. A. STAVROPOULOU, A. PHILIPPOU, A. HALAPAS, A. SOURLA, N. PISSIMISSIS, M. KOUTSILIERIS (<i>Athens, Greece</i>).....	647
CD95 and TNFα-induced Apoptosis in Liver Metastases of Colorectal Carcinoma. H.-U. KASPER, E. KONZE, M. KERN, D.L. STIPPEL (<i>Münster; Köln; Heidelberg, Germany</i>).....	653
Transplanted Mesenchymal Stem Cells Can Inhibit the Three Developmental Stages of Murine Acute Graft-versus-Host Disease. H. LI, Z. GUO, H. ZHU, X.S. LI, X. JIANG, H. YAO, X. WANG, L. LIAO, Y. LIU, Y. WU, Y. ZHANG, N. MAO (<i>Beijing, P.R. China</i>).....	659
Apoptosis and Cell Proliferation Correlated with Tumor Grade in Patients with Lung Adenocarcinoma. A. KALOGERAKI, M. TZARDI, O. ZORAS, E. GIANNIKAKI, M. PAPADAKIS, D. TAMIOLAKIS, P.E. PETRAKI, A. DIAMANTIS, N. SIAFAKAS, E. STATHOPOULOS (<i>Heraklion; Athens, Greece</i>).....	667
Novel Microminipig Model of Atherosclerosis by High Fat and High Cholesterol Diet, Established in Japan. N. MIYOSHI, M. HORIUCHI, Y. INOKUCHI, Y. MIYAMOTO, N. MIURA, S. TOKUNAGA, M. FUJIKI, Y. IZUMI, H. MIYAJIMA, R. NAGATA, K. MISUMI, T. TAKEUCHI, A. TANIMOTO, N. YASUDA, H. YOSHIDA, H. KAWAGUCHI (<i>Kagoshima; Osaka, Japan</i>).....	671

Scintigraphic Assessment of Salivary Gland Function in a Rat Model. A. PFESTROFF, F. MÜLLER, D. LIBRIZZI, B. EIVAZI, M. BEHE, H. HOEFFKEN, T.M. BEHR, A. TEYMOORTASH (<i>Marburg; Freiburg, Germany</i>)	681
Certain Surfactants Show Promise in the Therapy of Pulmonary Tuberculosis. J.K. STOOPS, R. ARORA, L. ARMITAGE, A. WANGER, L. SONG, M.R. BLACKBURN, G.R. KRUEGER, S.A. RISIN (<i>Houston; San Antonio, TX; Lexington, KY, USA</i>).....	687
Inhibin/Activin-betaC Subunit in Human Endometrial Adenocarcinomas and HEC-1a Adenocarcinoma Cell Line. S.D. KÄUFL, J. MAKOVITZKY, C. KUHN, S. KUNZE, U. JESCHKE, I. MYLONAS (<i>Munich; Heidelberg, Germany</i>).....	695
Diffuse Alveolar Damage due to Inappropriate Strategy of Mechanical Ventilation in an Experimental Porcine Model. J. KOBR, V. KUNTSCHER, J. MOLACEK, O. HES, K. PIZINGEROVA, J. KOCOVA, O. TOPOLCAN (<i>Prague; Pilsen, Czech Republic</i>)	699
A Simple Method to Record Parietal Cells in the Fundic Mucosa in Baboons. C.A. RUBIO, M. OWSTON, A. ORREGO, E.J. DICK Jr. (<i>San Antonio, TX, USA</i>).....	705
Effect of Itraconazoles on the Production of Pro-inflammatory Substances in Mouse Macrophage-like Cells. T. KATO, N. HORIE, K. HASHIMOTO, K. SATOH, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>).....	709
Isochromosome 5p, A Novel Recurrent Abnormality in Breast Cancer: Is it a Common Abnormality in Cancer? A.D. PANANI (<i>Athens, Greece</i>).....	715
Immediate and Short-, Mid- and Long-term Effects of <i>In Vivo</i> Ionizing Radiation Exposure in BALB/c Mice: I. Activation of Lymphocytes and Subpopulations. J. HERNANDEZ-GODOY, D. PLANELLES SILVESTRE, B. BALSALOBRE HERNANDEZ (<i>Valencia, Spain</i>).....	719
Metabolite Formation of 17 α -Hydroxyprogesterone as a Consequence of e _{-aq} -Emission and Progesterone Effect Regarding Cancer. N. GETOFF, I. DANIELOVA, J. HARTMANN, H. SCHITTL, M. GERSCHPACHER, S. YING, R. QUINT, J.C. HUBER (<i>Vienna, Austria</i>).....	727
Multiple Biological Complex of Alkaline Extract of the Leaves of <i>Sasa senanensis</i> Rehder. H. SAKAGAMI, L. ZHOU, M. KAWANO, M.M. THET, S. TANAKA, M. MACHINO, S. AMANO, R. KUROSHITA, S. WATANABE, Q. CHU, Q.-T. WANG, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, K. SEKINE, Y. SHIRATAKI, C.-H. ZHANG, Y. UESAWA, K. MOHRI, M. KITAJIMA, H. OIZUMI, T. OIZUMI (<i>Shaanxi; Yanji, P.R. China; Saitama; Kanagawa; Tokyo, Japan</i>)	735
Successful Anatomic Repair of Fetoscopic Access Sites in the Midgestational Rabbit Model Using Amnion Cell Engineering. N.A. PAPADOPULOS, D.I. KYRIAKIDIS, U. SCHILLINGER, A. TOTIS, J. HENKE, L. KOVACS, R.E. HORCH, K.T.M. SCHNEIDER, H.-G. MACHENS, E. BIEMER (<i>Munich; Erlangen, Germany</i>)	745
Non-antibiotics Reverse Resistance of Bacteria to Antibiotics. J.E. KRISTIANSEN, V.F. THOMSEN, A. MARTINS, M. VIVEIROS, L. AMARAL (<i>Odense; Copenhagen, Denmark; Lisbon, Portugal</i>).....	751
Association of Vitamin D Receptor Taq I Polymorphism and Susceptibility to Oral Squamous Cell Carcinoma. K. BEKTAŞ-KAYHAN, M. ÜNÜR, İ. YAYLIM-ERALTAN, H.A. ERGEN, B. TOPTAŞ, G. HAFIZ, A. KARADENİZ, T. İSBİR (<i>İstanbul, Turkey</i>)	755

Clinical Studies

* Review: Comorbidity of Personality Disorders with Alcohol Abuse. E. MELLOS, I. LIAPPAS, T. PAPARRIGOPOULOS (*Athens, Greece*)..... 761

* Short Review: Diagnostics of Neuroendocrine Tumours. M. HODOLIČ, J. FETTICH, E. BANTI, S. CHONDROGIANNIS, A. AL-NAHHAS, D. RUBELLO (*Ljubljana, Slovenia; Rovigo, Italy; London, UK*) 771

Relationship between Body Mass Index, Age and Hypoxemia in Patients with Extremely Severe Obesity Undergoing Bariatric Surgery. F. LUMACHI, B. MARZANO, G. FANTI, S.M.M. BASSO, F. MAZZA, G.B. CHIARA (*Padova; Pordenone, Italy*)..... 775

Ulnar Artery Thrombosis and Nerve Entrapment at Guyon’ s Canal: Our Diagnostic and Therapeutic Algorithm. G. MONACELLI, M.I. RIZZO, A.M. SPAGNOLI, C. MONARCA, N. SCUDERI (*Rome, Italy*)..... 779

Epithelioid Angiosarcoma of the Scapula. J. BÜRK, U. GERLACH, T. BAUMANN, M. LANGER, J.T. WINTERER (*Freiburg, Germany*)..... 783

Psychoneuroendocrine Modulation of Regulatory T Lymphocyte System: *In Vivo* and *In Vitro* Effects of the Pineal Immunomodulating Hormone Melatonin. L. VIGORÈ, G. MESSINA, F. BRIVIO, L. FUMAGALLI, F. ROVELLI, G. DI FEDE, P. LISSONI (*Milan, Italy*) 787

Metastatic Medullary Carcinoma of the Vulva in a Patient with MEN IIb Syndrome. N. THOMAKOS, A. RODOLAKIS, N. AKRIVOS, N. SKAMPARDONIS, M. SOTIROPOULOU, I. BILIATIS, M. ALEVIZAKI, A. ANTSAKLIS (*Athens, Greece*)..... 791

Smooth-Pursuit Eye Movement – A Convenient Bedside Indicator for Evaluating Frontal Lobe and Intellectual Function. K. SUDO, Y. MITO, Y. TAJIMA, A. MATSUMOTO, O. OIKAWA, K. TASHIRO (*Sapporo, Japan*)..... 795

Reduced Side-effects of Adjuvant Hormone Therapy in Breast Cancer Patients by Complementary Medicine. G. UHLENBRUCK, R. VAN LEENDERT, B. SCHNEIDER, J. BEUTH (*Cologne; Düsseldorf; Hannover, Germany*)..... 799

Depression, Anxiety and General Psychopathology in Breast Cancer Patients: A Cross-sectional Control Study. M. FAFOUTI, T. PAPARRIGOPOULOS, Y. ZERVAS, A. RABAVILAS, N. MALAMOS, I. LIAPPAS, C. TZAVARA (*Athens, Greece*) 803

* Reviews (pages 607, 761, 771)

Number 6

Experimental Studies

Intraesophageal Administration of GS-Nitroxide (JP4-039) Protects Against Ionizing Irradiation-induced Esophagitis. M.W. EPPERLY, J.P. GOFF, S. LI, X. GAO, P. WIPF, T. DIXON, H. WANG, D. FRANICOLA, H. SHEN, J.-C.M. RWIGEMA, V. KAGAN, M. BERNARD, J.S. GREENBERGER (*Pittsburgh, PA, USA*)..... 811

Comparison of the Degree of Hip Joint Luxation Induced by the Lateral and Medial Surgical Approaches Used to Generate Vascular Deprivation-induced Necrosis of the Femoral Head in Rats. J.M. KIM, T.S. HAN, J. PARK, B.C. SUTRADHAR, G. KIM, S.S. KANG, S.H. CHOI (*Cheongju; Gwangju, South Korea*)..... 821

Circadian Profile of Peripheral Hormone Levels in Sprague-Dawley Rats and in Common Marmosets (<i>Callithrix jacchus</i>). S. BERTANI, L. CARBONI, A. CRIADO, F. MICHIELIN, L. MANGIARINI, E. VICENTINI (<i>Verona, Italy</i>)	827
Diurnal Changes in Salivary Amino Acid Concentrations. Y. NAKAMURA, H. KODAMA, T. SATOH, K. ADACHI, S. WATANABE, Y. YOKOTE, H. SAKAGAMI (<i>Saitama, Japan</i>).....	837
Hormetic and Anti-radiation Effects of Tropolone-related Compounds. K. KANTOH, M. ONO, YUKO NAKAMURA, YUKIO NAKAMURA, K. HASHIMOTO, H. SAKAGAMI, H. WAKABAYASHI (<i>Saitama, Japan</i>).....	843
Changes in Salivary Amino Acid Composition During Aging. S. TANAKA, M. MACHINO, S. AKITA, Y. YOKOTE, H. SAKAGAMI (<i>Saitama, Japan</i>)	853
Changes in Amino Acid Metabolism During Activation of Mouse Macrophage-like Cell Lines. A. NISHIYAMA, Y. YOKOTE, H. SAKAGAMI (<i>Saitama, Japan</i>).....	857
<i>Clinical Studies</i>	
Urine and Serum Analysis of Consumed Curcuminoids Using an IκB-Luciferase Surrogate Marker Assay. S. PONNURANGAM, F.G. MONDALEK, J. GOVIND, D. SUBRAMANIAM, C.W. HOUCHEM, S. ANANT, P. PANTAZIS, R.P. RAMANUJAM (<i>Oklahoma City, OK, USA</i>).....	861
Nitric Oxide Concentrations Are Normal and Unrelated to Activity Level in Chronic Fatigue Syndrome: A Case-Control Study. M. MEEUS, I. VAN EUPEN, J. HONDEQUIN, L. DE HAUWERE, D. KOS, J. NIJS (<i>Merksem; Brussels, Belgium</i>).....	865
Atypical Plexiform Neurofibroma in NF1 with High Standardised Uptake Value (SUV) in Positron-Emission Tomography (PET) Expressing Podoplanin. R.E. FRIEDRICH, T. DERLIN, C. HAGEL (<i>Hamburg, Germany</i>).....	871
Desmoid-type Infantile Fibromatosis of the Mandible: Case Report with Long-term Follow-up. R.E. FRIEDRICH, U. GRZYSKA, H.A. SCHEUER, J. ZUSTIN (<i>Hamburg, Germany</i>).....	877
Oxidative Stress and Atherogenesis. An FT-IR Spectroscopic Study. I. MAMARELIS, K. PISSARIDI, V. DRITSA, P. KOTILEAS, V. TSILIGIRIS, V. TZILALIS, J. ANASTASSOPOULOU (<i>Athens, Greece</i>)....	883
Regeneration of Mandibular Osteoradionecrosis Defect with Platelet Rich Plasma Gel. M. SCALA, M. GIPPONI, P. MEREU, P. STRADA, R. CORVÒ, A. MURAGLIA, M. MASSA, S. BERTOGLIO, P. SANTI, F. CAFIERO (<i>Genoa, Italy</i>).....	889
Small Peripheral Developing Odontoma of the Maxilla in a 3-Year-Old Patient Depicted on Cone-Beam Tomograms. R.E. FRIEDRICH, A. FUHRMANN, H.A. SCHEUER, J. ZUSTIN (<i>Hamburg, Germany</i>).....	895
Life Stress and Losses and Deficit in Adulthood as Breast Cancer Risk Factor: A Prospective Case–Control Study in Kuopio, Finland. M. ESKELINEN, P. OLLONEN (<i>Kuopio, Finland</i>).....	899
Errata	905
Index 2010.....	907

Subject Index

(Figures refer to page numbers)

- A2, cyclin A2, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Abstracts of the 3rd Swedish-Hellenic Life Sciences Research Conference, March 25-27, 2010, Athens, Greece, 341-376
- Accelerometry, physical activity, ambulatory monitoring, nitric oxide, chronic fatigue syndrome, 865
- Activation, glycine, serine, macrophage, LPS, 857
- Acute graft-*versus*-host disease, antigen presenting cells, immunosuppressive, *in vivo*, mesenchymal stem cells, T lymphocyte, 659
- Acute infection, chronic fatigue syndrome, 185
- Acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Acute promyelocytic leukemia, APL, acute myeloid leukemia, AML, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Adenocarcinoma of lung, FNAB, apoptosis, TUNEL, MIB-1, 667
- Adjuvant hormone therapy, breast cancer, side-effects, complementary medicine, tolerability, 799
- AdOnco, database, head and neck cancer, documentation, 603
- Ageing, neuroendocrine immune system, lymphocyte populations, immune response, 471
- Aging, MRN-100, oxidative stress, antioxidants, 525
- Aging, saliva, amino acids, glycine, 853
- Alcohol abuse, biomarkers, CDT, IL-6, 325
- Alcohol abuse, personality, personality disorders, comorbidity, review, 761
- Alcohol abuse, Wernicke-Korsakoff syndrome, thiamine deficiency, treatment, reversibility, 231
- All-*trans* retinoic acid, ATRA, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Ambulatory monitoring, physical activity, accelerometry, nitric oxide, chronic fatigue syndrome, 865
- Ameloblastoma, dentigerous cyst, maxillary sinus tumor, calretinin, 3D-reconstruction of facial bone, 567
- Amino acid consumption, titanium, UV irradiation, cell attachment, MTT method, osteoblastic adhesion, 519
- Amino acid metabolism, titanium alloys, surface characteristics, osteoblast, glutamine, 29
- Amino acids, aging, saliva, glycine, 853
- Amino acids, diurnal change, saliva, student life, stress, 837
- 2-Aminotropones, tumor-specificity, hormesis, 39
- AML, acute myeloid leukemia, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Amnion cells, fetoscopy, fetal membranes, premature rupture of membranes, wound healing, tissue engineering, 745
- Analgesia, buprenorphine, corticosterone, cerebral ischaemia, refinement, 641
- Aneuploidy, chromosome X, GTG-banding, fluorescence *in situ* hybridization, schizophrenia, 281
- Angiogenesis, chronic hind limb ischemia, ischemia reperfusion injury, remote ischemic preconditioning, infarct size, arteriogenesis, 147
- Angiosarcoma of the bone, angiosarcoma, epithelioid angiosarcoma, 783
- Angiosarcoma, angiosarcoma of the bone, epithelioid angiosarcoma, 783
- Animal experiments, embryos, larvae, replacement, reduction, *Xenopus*, zebrafish, CAM, early life stage models, review, 457

- Animal model, nanoparticle, carcinogenesis, foreign body response, *in vivo* test, granuloma, mesothelioma, carbon nanotubes, 153
- Animal model, salivary gland, scintigraphy, rats, 681
- Anopheles gambiae*, malaria, mosquito, *Plasmodium berghei*, ookinete, midgut, 271
- Antibiotic, antifungal agent, radiation protection, radiation mitigators, bone marrow transplant, supportive care, 9
- Antibiotics, non-antibiotics, bacteria, reversal of resistance, 751
- Anticancer immunity, melatonin, pineal gland, regulatory T lymphocytes, 787
- Anticancer immunity, psychoncology, Rorschach's test, T-regulatory lymphocytes, 75
- Antifungal agent, antibiotic, radiation protection, radiation mitigators, bone marrow transplant, supportive care, 9
- Antigen presenting cells, acute graft-versus-host disease, immunosuppressive, *in vivo*, mesenchymal stem cells, T lymphocyte, 659
- Anti-HIV, LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, NO, macrophage, radical, ESR, lignin-like activity, 543
- Anti-idiotype vaccine, colon cancer immunogenicity, dendritic cell vaccine, autologous vaccine, review, 607
- Anti-inflammatory activity, *sasa senanensis* Rehder extract, chlorophyllin, lignin-carbohydrate complex, stomatitis, 735
- Antioxidant therapy, radiation protection, progenitor cells, gramicidin S, GS-nitroxide, esophagitis, 811
- Antioxidants, MRN-100, aging, oxidative stress, 525
- Antioxidants, radioprotectors, nitroxides, bone, 377
- Antisense oligonucleotides, prostate cancer, therapy, 489
- Antlerogenic cells, mesenchymal stem cells, bone reconstruction, rabbit, mandibular bone lesions, 165
- Anxiety, cancer, breast, oncology, depression, general psychopathology, 803
- APL, acute promyelocytic leukemia, acute myeloid leukemia, AML, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Apo B-100, hyperlipidemia, obesity, DGGE, gene polymorphism, *APOB*, 65a
- APOB*, Apo B-100, hyperlipidemia, obesity, DGGE, gene polymorphism, 65
- Apoptosis, adenocarcinoma of lung, FNAB, TUNEL, MIB-1, 667
- Apoptosis, gene expression profile, oxidative stress, proton radiation, rat retina, 425
- Apoptosis, liver metastases, colorectal cancer, PCTS, CD95, TNF α , 653
- Apoptosis, metals, cytotoxicity, human gingival fibroblast, HGF, autophagy, necrosis, 513
- Apoptosis, metals, cytotoxicity, osteoblastic cells, autophagy, necrosis, 507
- Apoptosis, vanillin, TRAIL, NF- κ B, cervical cancer, 501
- Arteriogenesis, chronic hind limb ischemia, angiogenesis, ischemia reperfusion injury, remote ischemic preconditioning, infarct size, 147
- Ascorbic acid, metastases, tumor, syngeneic, prostate, 249
- Atheromatic plaque, carotid, oxidative stress, free radicals, lipids, peroxidation, infrared, SEM, 883
- Atherosclerosis, cholesterol, diet, life-style, minipig, 671
- Atorvastatin, coronary artery disease, cellular adhesion molecules, leukocytes, inflammation, 189
- ATRA, all-*trans* retinoic acid, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Atypical neurofibroma, standardised uptake value, positron-emission tomography, malignant peripheral nerve sheath tumour, neurofibromatosis type 1, podoplanin, 871
- Auto-fluorescence, gastric mucosa, parietal cells, identification, baboons, fundic mucosa, 705
- Autologous vaccine, colon cancer immunogenicity, dendritic cell vaccine, anti-idiotype vaccine, review, 607
- Autophagy, metals, cytotoxicity, human gingival fibroblast, HGF, apoptosis, necrosis, 513
- Autophagy, metals, cytotoxicity, osteoblastic cells, apoptosis, necrosis, 507
- 5-Azacytidine, daidzein, genistein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- Baboons, gastric mucosa, parietal cells, auto-fluorescence, identification, fundic mucosa, 705
- Bacteria, non-antibiotics, antibiotics, reversal of resistance, 751
- Bacterial coat, *Mycobacterium tuberculosis*, trehalose dimycolate, octyl β -D-glucopyranoside, n-dodecyl β -D-maltoside, pulmonary tuberculosis, 687
- Bariatric surgery, hypoxemia, hypoventilation syndrome, obesity, body mass index, 329
- Bariatric surgery, obesity, hypoxemia, gastric by-pass, body mass index, excess weight, 775
- Behaviour, buprenorphine, surgery, corticosterone, rats, 131
- Biodiesel, renewable energy, glycerol, gene expression, *Gadd45a*, Nf κ b1, 303
- Biomarkers, alcohol abuse, CDT, IL-6, 325
- Birth order effect, CLL, heredity, pleiotropy, 85

- Body mass index, hypoxemia, hypoventilation syndrome, obesity, bariatric surgery, 329
- Body mass index, obesity, hypoxemia, bariatric surgery, gastric by-pass, excess weight, 775
- Bone marrow transplant, antibiotic, antifungal agent, radiation protection, radiation mitigators, supportive care, 9
- Bone reconstruction, mesenchymal stem cells, antlerogenic cells, rabbit, mandibular bone lesions, 165
- Bone tumour, hypercementosis, odontogenic epithelial hyperplasia, odontogenic tumour, 571
- Bone, radioprotectors, antioxidants, nitroxides, 377
- Brazil, methylation, P21^{CIP1}, P27^{KIP1}, immunohistochemistry, gastric cancer, 579
- BRCA1*, 5-azacytidine, daidzein, genistein, immunohistochemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, soy phytoestrogens, DNA methylation, 393
- Breast cancer, adjuvant hormone therapy, side-effects, complementary medicine, tolerability, 799
- Breast cancer, estrogen metabolism, genetic polymorphism, CYP17, CYP19, cytochrome P450, 71
- Breast cancer, genetic changes, chromosome 5 abnormalities, isochromosome 5p, G-banding technique, 715
- Breast cancer, guideline-based adjuvant treatment, immunosuppression, complementary treatment, 227
- Breast disease, psychosocial factors, stress, 899
- Breast, cancer, oncology, depression, anxiety, general psychopathology, 803
- Breast, veress needle, periprosthetic fluid, seroma, haematoma, 219
- Buprenorphine, analgesia, corticosterone, cerebral ischaemia, refinement, 641
- Buprenorphine, surgery, corticosterone, behaviour, rats, 131
- C/EBP ϵ , CCAAT/enhancer binding protein epsilon, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Caesarean section, umbilical cord blood donation, postpartal anaemia, maternal blood loss, haemoglobin, 339
- Calcitonin, multiple endocrine neoplasia, vulva, metastasis, 791
- Calretinin, ameloblastoma, dentigerous cyst, maxillary sinus tumor, 3D-reconstruction of facial bone, 567
- CAM, animal experiments, embryos, larvae, replacement, reduction, *Xenopus*, zebrafish, early life stage models, review, 457
- Cancer, breast, oncology, depression, anxiety, general psychopathology, 803
- Carbon dioxide therapy, chronic wounds, tissue hypoxia, 223
- Carbon nanotubes, animal model, nanoparticle, carcinogenesis, foreign body response, *in vivo* test, granuloma, mesothelioma, 153
- Carcinogenesis, animal model, nanoparticle, foreign body response, *in vivo* test, granuloma, mesothelioma, carbon nanotubes, 153
- Carcinogenicity, 17 α -hydroxyprogesterone, electron emission, oxygen sensitivity, hormone metabolites, 727
- Cardiac necrosis markers, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, ECG, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Carotid, atheromatic plaque, oxidative stress, free radicals, lipids, peroxidation, infrared, SEM, 883
- CCAAT/enhancer binding protein epsilon, C/EBP ϵ , acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- CCL2*, *CCR2*, polymorphism, endometrial cancer, chemokines, 243
- CCR2*, *CCL2*, polymorphism, endometrial cancer, chemokines, 243
- CD4⁺ cells, DPV576-C, nanodiamond, CD8⁺ cells, *in vivo*, 141
- CD40L, myeloma, gene therapy, plasmocytoma, 45
- CD8⁺ cells, DPV576-C, nanodiamond, CD4⁺ cells, *in vivo*, 141
- CD95, liver metastases, colorectal cancer, apoptosis, PCTS, TNF α , 653
- CDK1, cyclin dependent-kinase 1, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- CDK2, cyclin dependent-kinase 2, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21

- CDKN1A*, polymorphism, cell cycle, colorectal cancer risk, 179
- CDT, biomarkers, alcohol abuse, IL-6, 325
- Cell attachment, titanium, UV irradiation, MTT method, amino acid consumption, osteoblastic adhesion, 519
- Cell cycle arrest, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Cell cycle, *CDKN1A*, polymorphism, colorectal cancer risk, 179
- Cell cycle, oxytocin, estrogen, interleukin-2, lymphocytes, T-cell receptor, 157
- Cellular adhesion molecules, atorvastatin, coronary artery disease, leukocytes, inflammation, 189
- Central auditory processing disorders, fMRI, phonemic task, working memory, phonological store, dichotic listening, 201
- Cerebral ischaemia, analgesia, buprenorphine, corticosterone, refinement, 641
- Cervical cancer, vanillin, TRAIL, NF- κ B, apoptosis, 501
- Cetuximab, orthotopic tumors, MnSOD-PL, tirapazamine, gene therapy, 1
- Chemokines, *CCL2*, *CCR2*, polymorphism, endometrial cancer, 243
- Childhood, lung volumes, reference equations, pulmonary function test, 195
- Chlorophyllin, *sasa senanensis* Rehder extract, anti-inflammatory activity, lignin-carbohydrate complex, stomatitis, 735
- Cholesterol, atherosclerosis, diet, life-style, minipig, 671
- Chromosome 5 abnormalities, breast cancer, genetic changes, isochromosome 5p, G-banding technique, 715
- Chromosome X, aneuploidy, GTG-banding, fluorescence *in situ* hybridization, schizophrenia, 281
- Chronic fatigue syndrome, acute infection, 185
- Chronic fatigue syndrome, physical activity, accelerometry, ambulatory monitoring, nitric oxide, 865
- Chronic hind limb ischemia, angiogenesis, ischemia reperfusion injury, remote ischemic preconditioning, infarct size, arteriogenesis, 147
- Chronic wounds, carbon dioxide therapy, tissue hypoxia, 223
- Chronobiology, cortisol rhythm, melatonin, pineal gland, synchronization, 239
- Circadian rhythms, hormones, rat, marmoset, 827
- Clinical trial, curcumin, urinalysis, GEM assay, 861
- CLL, heredity, pleiotropy, birth order effect, 85
- Colon cancer immunogenicity, dendritic cell vaccine, autologous vaccine, anti-idiotypic vaccine, review, 607
- Colorectal cancer risk, *CDKN1A*, polymorphism, cell cycle, 179
- Colorectal cancer, liver metastases, apoptosis, PCTS, CD95, TNF α , 653
- Colorectal cancer, peritoneal carcinomatosis, HIPEC, cytoreductive surgery, 79
- Colorectal neoplasia, connexins, gap junctions, 101
- Comorbidity, alcohol abuse, personality, personality disorders, review, 761
- Complementary medicine, breast cancer, adjuvant hormone therapy, side-effects, tolerability, 799
- Complementary treatment, breast cancer, guideline-based adjuvant treatment, immunosuppression, 227
- Cone-beam tomography, peripheral odontogenic tumour, odontoma, 895
- Congenital lymphedema, FLT4 gene, Milroy disease, 309
- Conjunctival plaque, palpebral amyloidosis, eyelid ptosis, 575
- Connexins, gap junctions, colorectal neoplasia, 101
- Coronary artery disease, atorvastatin, cellular adhesion molecules, leukocytes, inflammation, 189
- Corticosterone, analgesia, buprenorphine, cerebral ischaemia, refinement, 641
- Corticosterone, buprenorphine, surgery, behaviour, rats, 131
- Cortisol rhythm, chronobiology, melatonin, pineal gland, synchronization, 239
- Critical size defect, osteoradionecrosis, mandible, platelet rich plasma, regeneration, 889
- Cryopreservation, fertility preservation, uterus, transplantation, female reproductive tract, 629
- C-troponin I, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, ECG, cardiac necrosis markers, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Culture media, indole-3-carbinol, I3C, diindolylmethane, DIM, linear trimer, 387
- Curcumin, clinical trial, urinalysis, GEM assay, 861
- Curcumin, meriva, mammary gland adenocarcinoma, metastasis, MMP-9, 401
- Cyanoacrylates, hypertrophic scar, scar management, scar topical therapy, silicone gel, 591
- Cyclin A1, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Cyclin A2, A2, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2,

- CDK2, cyclin A1, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , retinoid acid receptor, RXR, 21
- Cyclin dependent-kinase 1, CDK1, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , retinoid acid receptor, RXR, 21
- Cyclin dependent-kinase 2, CDK2, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , retinoid acid receptor, RXR, 21
- Cyclodextrin (HBC) effect, oxidizing and reducing free radicals, radical attack, 17 β -estradiol progesterone interaction, metabolite formation, 535
- Cyclophosphamide, β -glucan, G-CSF, hematopoiesis, granulopoiesis, monocyte, 59
- CYP17, estrogen metabolism, breast cancer, genetic polymorphism, CYP19, cytochrome P450, 71
- CYP19, estrogen metabolism, breast cancer, genetic polymorphism, CYP17, cytochrome P450, 71
- Cytochrome P450, estrogen metabolism, breast cancer, genetic polymorphism, CYP17, CYP19, 71
- Cytoreductive surgery, peritoneal carcinomatosis, HIPEC, colorectal cancer, 79
- Cytotoxicity, metals, human gingival fibroblast, HGF, apoptosis, autophagy, necrosis, 513
- Cytotoxicity, metals, osteoblastic cells, apoptosis, autophagy, necrosis, 507
- Daidzein, 5-azacytidine, genistein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- Database, AdOnco, head and neck cancer, documentation, 603
- Dendritic cell vaccine, colon cancer immunogenicity, autologous vaccine, anti-idiotypic vaccine, review, 607
- Dentigerous cyst, ameloblastoma, maxillary sinus tumor, calretinin, 3D-reconstruction of facial bone, 567
- Depression, cancer, breast, oncology, anxiety, general psychopathology, 803
- DGGE, Apo B-100, hyperlipidemia, obesity, gene polymorphism, *APOB*, 65
- Diagnosis, neuroendocrine tumours, somatostatin, scintigraphy, PET-DOTA peptides, short review, 771
- Dichotic listening, central auditory processing disorders, fMRI, phonemic task, working memory, phonological store, 201
- Diet, atherosclerosis, cholesterol, life-style, minipig, 671
- Differentiation, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , retinoid acid receptor, RXR, 21
- Diffuse alveolar damage, haemodynamics, mechanical ventilation, 699
- Diindolylmethane, indole-3-carbinol, I3C, DIM, culture media, linear trimer, 387
- DIM, indole-3-carbinol, I3C, diindolylmethane, culture media, linear trimer, 387
- 7,12-Dimethylbenz[α]anthracene, DMBA, endocrine disruptor, fetal, mammary tumor, 4-*n*-octylphenol, 463
- Diurnal change, saliva, amino acids, student life, stress, 837
- DMBA, 7,12-dimethylbenz[α]anthracene, endocrine disruptor, fetal, mammary tumor, 4-*n*-octylphenol, 463
- DNA damage, gypenosides, DNA repair gene, human oral cancer SAS cells, 287
- DNA methylation, 5-azacytidine, daidzein, genistein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, 393
- DNA repair gene, gypenosides, DNA damage, human oral cancer SAS cells, 287
- Documentation, AdOnco, database, head and neck cancer, 603
- DPV576-C, nanodiamond, CD4⁺ cells, CD8⁺ cells, *in vivo*, 141
- Drug-eluting stent, hemostasis, platelet activation, stent thrombosis, sirolimus-eluting stents, 635
- Early life stage models, animal experiments, embryos, larvae, replacement, reduction, *Xenopus*, zebrafish, CAM, review, 457
- ECG, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Efflux pumps, phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, XDR TB, human macrophage, enhanced killing activity by macrophage, therapy with thioridazine, review, 409
- Eicosapentaenoic acid, prostate cancer, prostate-specific antigen, omega-3 polyunsaturated fatty acids, 561

- Electron emission, 17 α -hydroxyprogesterone, oxygen sensitivity, hormone metabolites, carcinogenicity, 727
- 2-D Electrophoresis, MALDI-TOF, proteome, proteomics, *Tetrahymena thermophila*, TRI reagent, peptide finder, 443
- Embryos, animal experiments, larvae, replacement, reduction, *Xenopus*, zebrafish, CAM, early life stage models, review, 457
- Endocrine disruptor, 7,12-dimethylbenz[α]anthracene, DMBA, fetal, mammary tumor, 4-*n*-octylphenol, 463
- Endometrial cancer, *CCL2*, *CCR2*, polymorphism, chemokines, 243
- Endometrial carcinoma cell line, endometrioid adenocarcinomas, immunohistochemistry, immunofluorescence, inhibin-betaC, HEC-1a, 695
- Endometrioid adenocarcinomas, immunohistochemistry, immunofluorescence, inhibin-betaC, endometrial carcinoma cell line, HEC-1a, 695
- Endometriosis, *VEGF*, polymorphism, RFLP, 297
- Enhanced killing activity by macrophage, phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, XDR TB, human macrophage, efflux pumps, therapy with thioridazine, review, 409
- EPHB2*, 5-azacytidine, daidzein, genistein, immunohistochemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- Epithelioid angiosarcoma, angiosarcoma, angiosarcoma of the bone, 783
- Errata, 905
- Esophagitis, radiation protection, antioxidant therapy, progenitor cells, gramicidin S, GS-nitroxide, 811
- ESR, LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, anti-HIV, NO, macrophage, radical, lignin-like activity, 543
- 17 β -Estradiol, oxidizing and reducing free radicals, radical attack, metabolite formation, metabolites, 173
- 17 β -Estradiol progesterone interaction, oxidizing and reducing free radicals, radical attack, cyclodextrin (HBC) effect, metabolite formation, 535
- Estrogen metabolism, breast cancer, genetic polymorphism, CYP17, CYP19, cytochrome P450, 71
- Estrogen, oxytocin, interleukin-2, lymphocytes, T-cell receptor, cell cycle, 157
- Excess weight, obesity, hypoxemia, bariatric surgery, gastric by-pass, body mass index, 775
- Eye movement, intellectual function, frontal lobe function, primitive reflex, impairment in smooth-pursuit eye movement, 795
- Eyelid ptosis, palpebral amyloidosis, conjunctival plaque, 575
- Fatty acid, oestrogen, progesterone, rat, mammary cancer, 553
- Female reproductive tract, fertility preservation, uterus, transplantation, cryopreservation, 629
- Femoral head, hip joint luxation, osteonecrosis, rat, 821
- Fertility preservation, uterus, transplantation, cryopreservation, female reproductive tract, 629
- Fetal membranes, fetoscopy, premature rupture of membranes, wound healing, amnion cells, tissue engineering, 745
- Fetal, 7,12-dimethylbenz[α]anthracene, DMBA, endocrine disruptor, mammary tumor, 4-*n*-octylphenol, 463
- Fetoscopy, fetal membranes, premature rupture of membranes, wound healing, amnion cells, tissue engineering, 745
- Flavone, *scutellariae* radix, prostaglandin E2, structure-activity relationship, inhibition, 55
- FLT4 gene, congenital lymphedema, Milroy disease, 309
- Fluorescence *in situ* hybridization, aneuploidy, chromosome X, GTG-banding, schizophrenia, 281
- FMRI, central auditory processing disorders, phonemic task, working memory, phonological store, dichotic listening, 201
- FNAB, adenocarcinoma of lung, apoptosis, TUNEL, MIB-1, 667
- FNAC, thyroid lesions, surgery, management, 333
- Follicular fluid, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, polycystic ovary syndrome, *in vitro* fertilisation, 293
- Foreign body response, animal model, nanoparticle, carcinogenesis, *in vivo* test, granuloma, mesothelioma, carbon nanotubes, 153
- Free radicals, carotid, atheromatic plaque, oxidative stress, lipids, peroxidation, infrared, SEM, 883
- Frontal lobe function, intellectual function, primitive reflex, eye movement, impairment in smooth-pursuit eye movement, 795
- Frozen section, gangliocytic paraganglioma, neuroendocrine tumour, 321
- Fundic mucosa, gastric mucosa, parietal cells, auto-fluorescence, identification, baboons, 705
- Gadd45a*, renewable energy, biodiesel, glycerol, gene expression, Nfkb1, 303
- Gallbladder carcinoma, metachronous metastasis, long-term survival, 215
- Gamma probe, neuroendocrine tumours, NET, radioguided surgery, radionuclide therapy, review, 97
- Gangliocytic paraganglioma, frozen section, neuroendocrine tumour, 321
- Gap junctions, connexins, colorectal neoplasia, 101
- Gastric biopsies, parietal cells, identification, 599
- Gastric by-pass, obesity, hypoxemia, bariatric surgery, body mass index, excess weight, 775
- Gastric cancer, methylation, P21^{CIP1}, P27^{KIP1}, immunohistochemistry, Brazil, 579
- Gastric mucosa, parietal cells, auto-fluorescence, identification, baboons, fundic mucosa, 705

- Gastrointestinal stromal tumors, simultaneous neoplasm, GIST-other tumor association, IHC, mutation analysis, 109
- G-banding technique, breast cancer, genetic changes, chromosome 5 abnormalities, isochromosome 5p, 715
- G-CSF, β -glucan, hematopoiesis, granulopoiesis, cyclophosphamide, monocyte, 59
- GEM assay, curcumin, clinical trial, urinalysis, 861
- Gene expression profile, apoptosis, oxidative stress, proton radiation, rat retina, 425
- Gene expression, renewable energy, biodiesel, glycerol, *Gadd45a*, Nfkb1, 303
- Gene polymorphism, Apo B-100, hyperlipidemia, obesity, DGGE, *APOB*, 65
- Gene therapy, myeloma, CD40L, plasmocytoma, 45
- Gene therapy, orthotopic tumors, MnSOD-PL, cetuximab, tirapazamine, 1
- General psychopathology, cancer, breast, oncology, depression, anxiety, 803
- Genetic changes, breast cancer, chromosome 5 abnormalities, isochromosome 5p, G-banding technique, 715
- Genetic polymorphism, estrogen metabolism, breast cancer, CYP17, CYP19, cytochrome P450, 71
- Genistein, 5-azacytidine, daidzein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- GIST-other tumor association, gastrointestinal stromal tumors, simultaneous neoplasm, IHC, mutation analysis, 109
- B-Glucan, G-CSF, hematopoiesis, granulopoiesis, cyclophosphamide, monocyte, 59
- Glutamine, titanium alloys, surface characteristics, osteoblast, amino acid metabolism, 29
- Glycerol, renewable energy, biodiesel, gene expression, *Gadd45a*, Nfkb1, 303
- Glycine, aging, saliva, amino acids, 853
- Glycine, serine, macrophage, activation, LPS, 857
- Gramicidin S, radiation protection, antioxidant therapy, progenitor cells, GS-nitroxide, esophagitis, 811
- Granuloma, animal model, nanoparticle, carcinogenesis, foreign body response, *in vivo* test, mesothelioma, carbon nanotubes, 153
- Granulocyte, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , retinoid acid receptor, RXR, 21
- Granulopoiesis, β -glucan, G-CSF, hematopoiesis, cyclophosphamide, monocyte, 59
- GS-nitroxide, radiation protection, antioxidant therapy, progenitor cells, gramicidin S, esophagitis, 811
- GSTP1*, 5-azacytidine, daidzein, genistein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- GTG-banding, aneuploidy, chromosome X, fluorescence *in situ* hybridization, schizophrenia, 281
- Guideline-based adjuvant treatment, breast cancer, immunosuppression, complementary treatment, 227
- Guyon's canal, ulnar artery thrombosis, ulnar nerve entrapment, 779
- Gyposides, DNA damage, DNA repair gene, human oral cancer SAS cells, 287
- Haematoma, veress needle, periprosthetic fluid, breast, seroma, 219
- Haemodynamics, diffuse alveolar damage, mechanical ventilation, 699
- Haemoglobin, umbilical cord blood donation, postpartal anaemia, caesarean section, maternal blood loss, 339
- Head and neck cancer, AdOnco, database, documentation, 603
- HEC-1a, endometrioid adenocarcinomas, immunohistochemistry, immunofluorescence, inhibin-betaC, endometrial carcinoma cell line, 695
- Hematopoiesis, β -glucan, G-CSF, granulopoiesis, cyclophosphamide, monocyte, 59
- Hemostasis, drug-eluting stent, platelet activation, stent thrombosis, sirolimus-eluting stents, 635
- Hepatocellular carcinoma, oral metastasis, palliative treatment of oral cancer, 211
- Heredity, CLL, pleiotropy, birth order effect, 85
- HGF, metals, cytotoxicity, human gingival fibroblast, apoptosis, autophagy, necrosis, 513
- Hip joint luxation, femoral head, osteonecrosis, rat, 821
- HIPEC, peritoneal carcinomatosis, cytoreductive surgery, colorectal cancer, 79
- Histology, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, ECG, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Hormesis, 2-aminotropones, tumor-specificity, 39
- Hormesis, tropones, UV protection, 843
- Hormone metabolites, 17 α -hydroxyprogesterone, electron emission, oxygen sensitivity, carcinogenicity, 727
- Hormones, circadian rhythms, rat, marmoset, 827
- Human gingival fibroblast, metals, cytotoxicity, HGF, apoptosis, autophagy, necrosis, 513
- Human macrophage, phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, XDR TB, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, review, 409
- Human oral cancer SAS cells, gyposides, DNA damage, DNA repair gene, 287

- Hydroxyitraconazole, itraconazole, macrophage, NO, PGE₂, IL-1β, TNF-α, pro-inflammatory substances, 709
- 17α-Hydroxyprogesterone, electron emission, oxygen sensitivity, hormone metabolites, carcinogenicity, 727
- Hypercementosis, odontogenic epithelial hyperplasia, odontogenic tumour, bone tumour, 571
- Hyperlipidemia, Apo B-100, obesity, DGGE, gene polymorphism, *APOB*, 65
- Hypertrophic scar, scar management, scar topical therapy, cyanoacrylates, silicone gel, 591
- Hypoventilation syndrome, hypoxemia, obesity, bariatric surgery, body mass index, 329
- Hypoxemia, hypoventilation syndrome, obesity, bariatric surgery, body mass index, 329
- Hypoxemia, obesity, bariatric surgery, gastric by-pass, body mass index, excess weight, 775
- I3C, indole-3-carbinol, diindolylmethane, DIM, culture media, linear trimer, 387
- Identification, gastric biopsies, parietal cells, 599
- Identification, gastric mucosa, parietal cells, auto-fluorescence, baboons, fundic mucosa, 705
- IFN-γ, IL-1β, IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, TNF-α, immune response, 117
- IHC, gastrointestinal stromal tumors, simultaneous neoplasm, GIST-other tumor association, mutation analysis, 109
- IL-1β, hydroxyitraconazole, itraconazole, macrophage, NO, PGE₂, TNF-α, pro-inflammatory substances, 709
- IL-1β, IFN-γ, IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, TNF-α, immune response, 117
- IL-2, IFN-γ, IL-1β, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, TNF-α, immune response, 117
- IL-4, IFN-γ, IL-1β, IL-2, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, TNF-α, immune response, 117
- IL-6, biomarkers, alcohol abuse, CDT, 325
- IL-6, IFN-γ, IL-1β, IL-2, IL-4, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, TNF-α, immune response, 117
- Immune response, IFN-γ, IL-1β, IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, TNF-α, 117
- Immune response, neuroendocrine immune system, lymphocyte populations, ageing, 471
- Immunofluorescence, endometrioid adenocarcinomas, immunohistochemistry, inhibin-betaC, endometrial carcinoma cell line, HEC-1a, 695
- Immunohisto-chemistry, 5-azacytidine, daidzein, genistein, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- Immunohistochemistry, endometrioid adenocarcinomas, immunofluorescence, inhibin-betaC, endometrial carcinoma cell line, HEC-1a, 695
- Immunohisto-chemistry, infantile fibromatosis, jaw tumour, panoramic radiograph, 877
- Immunohistochemistry, methylation, P21^{CIP1}, P27^{KIP1}, gastric cancer, Brazil, 579
- Immunohistochemistry, squamous cell carcinomas, tissue microarray, p53, p16, p21, Rb, 315
- Immunosuppression, breast cancer, guideline-based adjuvant treatment, complementary treatment, 227
- Immunosuppressive, acute graft-versus-host disease, antigen presenting cells, *in vivo*, mesenchymal stem cells, T lymphocyte, 659
- Impairment in smooth-pursuit eye movement, intellectual function, frontal lobe function, primitive reflex, eye movement, 795
- In vitro* fertilisation, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, follicular fluid, polycystic ovary syndrome, 293
- In vivo* test, animal model, nanoparticle, carcinogenesis, foreign body response, granuloma, mesothelioma, carbon nanotubes, 153
- In vivo*, acute graft-versus-host disease, antigen presenting cells, immunosuppressive, mesenchymal stem cells, T lymphocyte, 659
- In vivo*, DPV576-C, nanodiamond, CD4⁺ cells, CD8⁺ cells, 141
- Indole-3-carbinol, I3C, diindolylmethane, DIM, culture media, linear trimer, 387
- Infantile fibromatosis, jaw tumour, immunohisto-chemistry, panoramic radiograph, 877
- Infarct size, chronic hind limb ischemia, angiogenesis, ischemia reperfusion injury, remote ischemic preconditioning, arteriogenesis, 147
- Inflammation, atorvastatin, coronary artery disease, cellular adhesion molecules, leukocytes, 189
- Infrared, carotid, atheromatic plaque, oxidative stress, free radicals, lipids, peroxidation, SEM, 883
- Inhibin-betaC, endometrioid adenocarcinomas, immunohistochemistry, immunofluorescence, endometrial carcinoma cell line, HEC-1a, 695
- Inhibition, *scutellariae* radix, prostaglandin E2, structure-activity relationship, flavone, 55
- Intellectual function, frontal lobe function, primitive reflex, eye movement, impairment in smooth-pursuit eye movement, 795
- Interleukin-1β, tumor necrosis factor, interleukin-6, IVF, pregnancy, 495
- Interleukin-2, oxytocin, estrogen, lymphocytes, T-cell receptor, cell cycle, 157
- Interleukin-6, interleukin-1β, tumor necrosis factor, IVF, pregnancy, 495
- Ionizing radiation, lymphocytes, subsets, whole-body irradiation, WBI, 719
- Ischemia reperfusion injury, chronic hind limb ischemia, angiogenesis, remote ischemic preconditioning, infarct size, arteriogenesis, 147

- Isochromosome 5p, breast cancer, genetic changes, chromosome 5 abnormalities, G-banding technique, 715
- Isoproterenol, myocardial infarction, *tetrandrine*, rabbits, histology, ECG, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Itraconazole, hydroxyitraconazole, macrophage, NO, PGE₂, IL-1 β , TNF- α , pro-inflammatory substances, 709
- IVF, interleukin-1 β , tumor necrosis factor, interleukin-6, pregnancy, 495
- Jaw tumour, infantile fibromatosis, immunohisto-chemistry, panoramic radiograph, 877
- Larvae, animal experiments, embryos, replacement, reduction, *Xenopus*, zebrafish, CAM, early life stage models, review, 457
- LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, anti-HIV, NO, macrophage, radical, ESR, lignin-like activity, 543
- Lentinus edodes* mycelia, LEM, lignin carbohydrate complex, anti-HIV, NO, macrophage, radical, ESR, lignin-like activity, 543
- Leukocytes, atorvastatin, coronary artery disease, cellular adhesion molecules, inflammation, 189
- Life-style, atherosclerosis, cholesterol, diet, minipig, 671
- Lignin carbohydrate complex, LEM, *Lentinus edodes* mycelia, anti-HIV, NO, macrophage, radical, ESR, lignin-like activity, 543
- Lignin-carbohydrate complex, *sasa senanensis* Rehder extract, anti-inflammatory activity, chlorophyllin, stomatitis, 735
- Lignin-like activity, LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, anti-HIV, NO, macrophage, radical, ESR, 543
- Linear trimer, indole-3-carbinol, I3C, diindolylmethane, DIM, culture media, 387
- Lipids, carotid, atheromatic plaque, oxidative stress, free radicals, peroxidation, infrared, SEM, 883
- Liver metastases, colorectal cancer, apoptosis, PCTS, CD95, TNF α , 653
- Long-term survival, gallbladder carcinoma, metachronous metastasis, 215
- LPS, glycine, serine, macrophage, activation, 857
- Lung volumes, reference equations, pulmonary function test, childhood, 195
- Lymphocyte populations, neuroendocrine immune system, ageing, immune response, 471
- T lymphocyte, acute graft-*versus*-host disease, antigen presenting cells, immunosuppressive, *in vivo*, mesenchymal stem cells, 659
- Lymphocytes, ionizing radiation, subsets, whole-body irradiation, WBI, 719
- Lymphocytes, oxytocin, estrogen, interleukin-2, T-cell receptor, cell cycle, 157
- Macrophage, glycine, serine, activation, LPS, 857
- Macrophage, hydroxyitraconazole, itraconazole, NO, PGE₂, IL-1 β , TNF- α , pro-inflammatory substances, 709
- Macrophage, LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, anti-HIV, NO, radical, ESR, lignin-like activity, 543
- Malaria, mosquito, *Anopheles gambiae*, *Plasmodium berghei*, ookinete, midgut, 271
- MALDI-TOF, proteome, proteomics, *Tetrahymena thermophila*, TRI reagent, 2-D electrophoresis, peptide finder, 443
- Malignant peripheral nerve sheath tumour, standardised uptake value, positron-emission tomography, atypical neurofibroma, neurofibromatosis type 1, podoplanin, 871
- Malondialdehyde, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, ECG, cardiac necrosis markers, c-troponin I, myoglobin, partial thromboplastin time, 265
- Mammary cancer, oestrogen, progesterone, fatty acid, rat, 553
- Mammary gland adenocarcinoma, meriva, curcumin, metastasis, MMP-9, 401
- Mammary tumor, 7,12-dimethylbenz[α]anthracene, DMBA, endocrine disruptor, fetal, 4-*n*-octylphenol, 463
- Management, thyroid lesions, FNAC, surgery, 333
- Mandible, osteoradionecrosis, critical size defect, platelet rich plasma, regeneration, 889
- Mantibular bone lesions, mesenchymal stem cells, bone reconstruction, antlerogenic cells, rabbit, 165
- Marmoset, circadian rhythms, hormones, rat, 827
- Maternal blood loss, umbilical cord blood donation, postpartal anaemia, caesarean section, haemoglobin, 339
- Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, follicular fluid, polycystic ovary syndrome, *in vitro* fertilisation, 293
- Maxillary sinus tumor, ameloblastoma, dentigerous cyst, calretinin, 3D-reconstruction of facial bone, 567
- MDR TB, phenothiazines, thioridazine, pulmonary tuberculosis, XDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, review, 409
- Mechanical ventilation, diffuse alveolar damage, haemodynamics, 699
- Melatonin, anticancer immunity, pineal gland, regulatory T lymphocytes, 787
- Melatonin, chronobiology, cortisol rhythm, pineal gland, synchronization, 239
- Meriva, curcumin, mammary gland adenocarcinoma, metastasis, MMP-9, 401
- Mesenchymal stem cells, acute graft-*versus*-host disease, antigen presenting cells, immunosuppressive, *in vivo*, T lymphocyte, 659
- Mesenchymal stem cells, bone reconstruction, antlerogenic cells, rabbit, mantibular bone lesions, 165

- Mesothelioma, animal model, nanoparticle, carcinogenesis, foreign body response, *in vivo* test, granuloma, carbon nanotubes, 153
- Metabolite formation, oxidizing and reducing free radicals, radical attack, 17 β -estradiol progesterone interaction, cyclodextrin (HBC) effect, 535
- Metabolite formation, oxidizing and reducing free radicals, radical attack, 17 β -estradiol, metabolites, 173
- Metabolites, oxidizing and reducing free radicals, radical attack, 17 β -estradiol, metabolite formation, 173
- Metachronous metastasis, gallbladder carcinoma, long-term survival, 215
- Metals, cytotoxicity, human gingival fibroblast, HGF, apoptosis, autophagy, necrosis, 513
- Metals, cytotoxicity, osteoblastic cells, apoptosis, autophagy, necrosis, 507
- Metastases, ascorbic acid, tumor, syngeneic, prostate, 249
- Metastasis, meriva, curcumin, mammary gland adenocarcinoma, MMP-9, 401
- Metastasis, multiple endocrine neoplasia, vulva, calcitonin, 791
- Methylation, P21^{CIP1}, P27^{KIP1}, immunohistochemistry, gastric cancer, Brazil, 579
- Methylation-specific-PCR, 5-azacytidine, daidzein, genistein, immunohisto-chemistry, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- MIB-1, adenocarcinoma of lung, FNAB, apoptosis, TUNEL, 667
- Midgut, malaria, mosquito, *Anopheles gambiae*, *Plasmodium berghei*, ookinete, 271
- Milroy disease, congenital lymphedema, FLT4 gene, 309
- Minipig, atherosclerosis, cholesterol, diet, life-style, 671
- MMP-9, meriva, curcumin, mammary gland adenocarcinoma, metastasis, 401
- MnSOD-PL, orthotopic tumors, cetuximab, tirapazamine, gene therapy, 1
- Monocyte, β -glucan, G-CSF, hematopoiesis, granulopoiesis, cyclophosphamide, 59
- Mosquito, malaria, *Anopheles gambiae*, *Plasmodium berghei*, ookinete, midgut, 271
- MRN-100, aging, oxidative stress, antioxidants, 525
- ^{99m}Tc-DMSA, ^{99m}Tc-DTPA, ^{99m}Tc-MAG3, renal function, rabbit, 137
- ^{99m}Tc-DTPA, ^{99m}Tc-DMSA, ^{99m}Tc-MAG3, renal function, rabbit, 137
- ^{99m}Tc-MAG3, ^{99m}Tc-DMSA, ^{99m}Tc-DTPA, renal function, rabbit, 137
- MTT method, titanium, UV irradiation, cell attachment, amino acid consumption, osteoblastic adhesion, 519
- Multiple endocrine neoplasia, vulva, metastasis, calcitonin, 791
- Muscle, regeneration, uterus, vessels, 431
- Mutation analysis, gastrointestinal stromal tumors, simultaneous neoplasm, GIST-other tumor association, IHC, 109
- Mycobacterium tuberculosis*, trehalose dimycolate, octyl β -D-glucopyranoside, n-dodecyl β -D-maltoside, bacterial coat, pulmonary tuberculosis, 687
- Myeloma, gene therapy, CD40L, plasmocytoma, 45
- Myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, ECG, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Myocardial infarction, TGF β ₁, uPA, uPAR, 647
- Myoglobin, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, ECG, cardiac necrosis markers, c-troponin I, malondialdehyde, partial thromboplastin time, 265
- Nanodiamond, DPV576-C, CD4⁺ cells, CD8⁺ cells, *in vivo*, 141
- Nanoparticle, animal model, carcinogenesis, foreign body response, *in vivo* test, granuloma, mesothelioma, carbon nanotubes, 153
- Natriuretic peptides, pancreatic cancer, new therapeutics, nu/nu mouse model, 125
- N-dodecyl β -D-maltoside, *mycobacterium tuberculosis*, trehalose dimycolate, octyl β -D-glucopyranoside, bacterial coat, pulmonary tuberculosis, 687
- Necrosis, metals, cytotoxicity, human gingival fibroblast, HGF, apoptosis, autophagy, 513
- Necrosis, metals, cytotoxicity, osteoblastic cells, apoptosis, autophagy, 507
- NET, neuroendocrine tumours, radioguided surgery, gamma probe, radionuclide therapy, review, 97
- Neuroendocrine immune system, lymphocyte populations, ageing, immune response, 471
- Neuroendocrine tumour, gangliocytic paraganglioma, frozen section, 321
- Neuroendocrine tumours, diagnosis, somatostatin, scintigraphy, PET-DOTA peptides, short review, 771
- Neuroendocrine tumours, NET, radioguided surgery, gamma probe, radionuclide therapy, review, 97
- Neurofibromatosis type 1, standardised uptake value, positron-emission tomography, atypical neurofibroma, malignant peripheral nerve sheath tumour, podoplanin, 871
- Neurotoxicity, nitric oxide, peroxyntirite, singlet oxygen, resveratrol, ultraviolet C radiation, rabbit brain synaptosomes, 49
- New therapeutics, pancreatic cancer, natriuretic peptides, nu/nu mouse model, 125
- NF-KB, vanillin, TRAIL, apoptosis, cervical cancer, 501
- Nfkb1, renewable energy, biodiesel, glycerol, gene expression, *Gadd45a*, 303
- Nitric oxide, peroxyntirite, singlet oxygen, resveratrol, ultraviolet C radiation, rabbit brain synaptosomes, neurotoxicity, 49

- Nitric oxide, physical activity, accelerometry, ambulatory monitoring, chronic fatigue syndrome, 865
- Nitroxides, radioprotectors, antioxidants, bone, 377
- NO, hydroxyitraconazole, itraconazole, macrophage, PGE₂, IL-1 β , TNF- α , pro-inflammatory substances, 709
- NO, LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, anti-HIV, macrophage, radical, ESR, lignin-like activity, 543
- Non-antibiotics, bacteria, antibiotics, reversal of resistance, 751
- Nu/nu mouse model, pancreatic cancer, new therapeutics, natriuretic peptides, 125
- Obesity, Apo B-100, hyperlipidemia, DGGE, gene polymorphism, *APOB*, 65
- Obesity, hypoxemia, bariatric surgery, gastric by-pass, body mass index, excess weight, 775
- Obesity, hypoxemia, hypoventilation syndrome, bariatric surgery, body mass index, 329
- Octyl β -D-glucopyranoside, *mycobacterium tuberculosis*, trehalose dimycolate, n-dodecyl β -D-maltoside, bacterial coat, pulmonary tuberculosis, 687
- 4-*n*-Octylphenol, 7,12-dimethylbenz[α]anthracene, DMBA, endocrine disruptor, fetal, mammary tumor, 463
- Odontogenic epithelial hyperplasia, hypercementosis, odontogenic tumour, bone tumour, 571
- Odontogenic tumour, hypercementosis, odontogenic epithelial hyperplasia, bone tumour, 571
- Odontoma, peripheral odontogenic tumour, cone-beam tomography, 895
- Oestrogen, progesterone, fatty acid, rat, mammary cancer, 553
- Omega-3 polyunsaturated fatty acids, prostate cancer, prostate-specific antigen, eicosapentaenoic acid, 561
- Oncology, cancer, breast, depression, anxiety, general psychopathology, 803
- Ookinete, malaria, mosquito, *Anopheles gambiae*, *Plasmodium berghei*, midgut, 271
- Oral metastasis, hepatocellular carcinoma, palliative treatment of oral cancer, 211
- Oral squamous cell carcinoma, vitamin D receptor, polymorphism, 755
- Orthotopic tumors, MnSOD-PL, cetuximab, tirapazamine, gene therapy, 1
- Osteoblast, titanium alloys, surface characteristics, amino acid metabolism, glutamine, 29
- Osteoblastic adhesion, titanium, UV irradiation, cell attachment, MTT method, amino acid consumption, 519
- Osteoblastic cells, metals, cytotoxicity, apoptosis, autophagy, necrosis, 507
- Osteomyelitis, porcine model, *Staphylococcus aureus*, pig, pyaemia, 257
- Osteonecrosis, femoral head, hip joint luxation, rat, 821
- Osteoradionecrosis, mandible, critical size defect, platelet rich plasma, regeneration, 889
- Oxidative stress, carotid, atheromatic plaque, free radicals, lipids, peroxidation, infrared, SEM, 883
- Oxidative stress, gene expression profile, apoptosis, proton radiation, rat retina, 425
- Oxidative stress, MRN-100, aging, antioxidants, 525
- Oxidizing and reducing free radicals, radical attack, 17 β -estradiol progesterone interaction, cyclodextrin (HBC) effect, metabolite formation, 535
- Oxidizing and reducing free radicals, radical attack, 17 β -estradiol, metabolite formation, metabolites, 173
- Oxygen sensitivity, 17 α -hydroxyprogesterone, electron emission, hormone metabolites, carcinogenicity, 727
- Oxytocin, estrogen, interleukin-2, lymphocytes, T-cell receptor, cell cycle, 157
- P16, squamous cell carcinomas, tissue microarray, immunohistochemistry, p53, p21, Rb, 315
- P21, squamous cell carcinomas, tissue microarray, immunohistochemistry, p53, p16, Rb, 315
- P21^{CIP1}, methylation, P27^{KIP1}, immunohistochemistry, gastric cancer, Brazil, 579
- P27^{KIP1}, methylation, P21^{CIP1}, immunohistochemistry, gastric cancer, Brazil, 579
- P53, squamous cell carcinomas, tissue microarray, immunohistochemistry, p16, p21, Rb, 315
- Palliative treatment of oral cancer, hepatocellular carcinoma, oral metastasis, 211
- Palpebral amyloidosis, eyelid ptosis, conjunctival plaque, 575
- Pancreatic cancer, new therapeutics, natriuretic peptides, nu/nu mouse model, 125
- Panoramic radiograph, infantile fibromatosis, jaw tumour, immunohisto-chemistry, 877
- Parietal cells, gastric biopsies, identification, 599
- Parietal cells, gastric mucosa, auto-fluorescence, identification, baboons, fundic mucosa, 705
- Partial thromboplastin time, myocardial infarction, isoproterenol, *tetrandrine*, rabbits, histology, ECG, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, 265
- PCTS, liver metastases, colorectal cancer, apoptosis, CD95, TNF α , 653
- peptide finder, MALDI-TOF, proteome, proteomics, *Tetrahymena thermophila*, TRI reagent, 2-D electrophoresis, 443
- Peripheral odontogenic tumour, cone-beam tomography, odontoma, 895
- Periprosthetic fluid, veress needle, breast, seroma, haematoma, 219
- Peritoneal carcinomatosis, HIPEC, cytoreductive surgery, colorectal cancer, 79
- Peroxidation, carotid, atheromatic plaque, oxidative stress, free radicals, lipids, infrared, SEM, 883

- Peroxynitrite, nitric oxide, singlet oxygen, resveratrol, ultraviolet C radiation, rabbit brain synaptosomes, neurotoxicity, 49
- Personality disorders, alcohol abuse, personality, comorbidity, review, 761
- Personality, alcohol abuse, personality disorders, comorbidity, review, 761
- PET, PET/CT, thoracic malignancies, 235
- PET/CT, PET, thoracic malignancies, 235
- PET-DOTA peptides, neuroendocrine tumours, diagnosis, somatostatin, scintigraphy, short review, 771
- PGE₂, hydroxyitraconazole, itraconazole, macrophage, NO, IL-1 β , TNF- α , pro-inflammatory substances, 709
- Phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, XDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, review, 409
- Phonemic task, central auditory processing disorders, fMRI, working memory, phonological store, dichotic listening, 201
- Phonological store, central auditory processing disorders, fMRI, phonemic task, working memory, dichotic listening, 201
- Physical activity, accelerometry, ambulatory monitoring, nitric oxide, chronic fatigue syndrome, 865
- Pig, osteomyelitis, porcine model, *Staphylococcus aureus*, pyaemia, 257
- Pilonidal sinus, platelet gel, surgical technique, Vivostat™, 583
- Pineal gland, anticancer immunity, melatonin, regulatory T lymphocytes, 787
- Pineal gland, chronobiology, cortisol rhythm, melatonin, synchronization, 239
- Plasmocytoma, myeloma, gene therapy, CD40L, 45
- Plasmodium berghei*, malaria, mosquito, *Anopheles gambiae*, ookinete, midgut, 271
- Platelet activation, drug-eluting stent, hemostasis, stent thrombosis, sirolimus-eluting stents, 635
- Platelet gel, pilonidal sinus, surgical technique, Vivostat™, 583
- Platelet rich plasma, osteoradionecrosis, mandible, critical size defect, regeneration, 889
- Pleiotropy, CLL, heredity, birth order effect, 85
- PLZF, promyelocytic leukemia zinc finger protein, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- PM, promyelocyte, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- PML-RAR α , acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Podoplanin, standardised uptake value, positron-emission tomography, atypical neurofibroma, malignant peripheral nerve sheath tumour, neurofibromatosis type 1, 871
- Polycystic ovary syndrome, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, follicular fluid, *in vitro* fertilisation, 293
- Polymorphism, *CCL2*, *CCR2*, endometrial cancer, chemokines, 243
- Polymorphism, *CDKN1A*, cell cycle, colorectal cancer risk, 179
- Polymorphism, *VEGF*, endometriosis, RFLP, 297
- Polymorphism, vitamin D receptor, oral squamous cell carcinoma, 755
- Porcine model, osteomyelitis, *Staphylococcus aureus*, pig, pyaemia, 257
- Positron-emission tomography, standardised uptake value, atypical neurofibroma, malignant peripheral nerve sheath tumour, neurofibromatosis type 1, podoplanin, 871
- Postpartal anaemia, umbilical cord blood donation, caesarean section, maternal blood loss, haemoglobin, 339
- Pregnancy, interleukin-1 β , tumor necrosis factor, interleukin-6, IVF, 495
- Premature rupture of membranes, fetoscopy, fetal membranes, wound healing, amnion cells, tissue engineering, 745
- Primitive reflex, intellectual function, frontal lobe function, eye movement, impairment in smooth-pursuit eye movement, 795
- Progenitor cells, radiation protection, antioxidant therapy, gramicidin S, GS-nitroxide, esophagitis, 811
- Progesterone, oestrogen, fatty acid, rat, mammary cancer, 553
- Pro-inflammatory substances, hydroxyitraconazole, itraconazole, macrophage, NO, PGE₂, IL-1 β , TNF- α , 709
- Promyelocyte, PM, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21

- Promyelocytic leukemia zinc finger protein, PLZF, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, retinoic acid receptor α , RAR α , rexinoid acid receptor, RXR, 21
- Prostaglandin E2, *scutellariae* radix, structure-activity relationship, inhibition, flavone, 55
- Prostate cancer, 5-azacytidine, daidzein, genistein, immunohisto-chemistry, methylation-specific-PCR, *GSTPI*, *EPHB2*, *RASSF1A*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- Prostate cancer, antisense oligonucleotides, therapy, 489
- Prostate cancer, prostate-specific antigen, eicosapentaenoic acid, omega-3 polyunsaturated fatty acids, 561
- Prostate, ascorbic acid, metastases, tumor, syngeneic, 249
- Prostate-specific antigen, prostate cancer, eicosapentaenoic acid, omega-3 polyunsaturated fatty acids, 561
- Proteome, MALDI-TOF, proteomics, *Tetrahymena thermophila*, TRI reagent, 2-D electrophoresis, peptide finder, 443
- Proteomics, MALDI-TOF, proteome, *Tetrahymena thermophila*, TRI reagent, 2-D electrophoresis, peptide finder, 443
- Proton radiation, gene expression profile, apoptosis, oxidative stress, rat retina, 425
- Psychoncology, anticancer immunity, Rorschach's test, T-regulatory lymphocytes, 75
- Psychosocial factors, breast disease, stress, 899
- Pulmonary function test, lung volumes, reference equations, childhood, 195
- Pulmonary tuberculosis, *mycobacterium tuberculosis*, trehalose dimycolate, octyl β -D-glucopyranoside, n-dodecyl β -D-maltoside, bacterial coat, 687
- Pulmonary tuberculosis, phenothiazines, thioridazine, MDR TB, XDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, review, 409
- Pyemia, osteomyelitis, porcine model, *Staphylococcus aureus*, pig, 257
- Rabbit brain synaptosomes, nitric oxide, peroxynitrite, singlet oxygen, resveratrol, ultraviolet C radiation, neurotoxicity, 49
- Rabbit, ^{99m}Tc -DMSA, ^{99m}Tc -DTPA, ^{99m}Tc -MAG3, renal function, 137
- Rabbit, mesenchymal stem cells, bone reconstruction, antlerogenic cells, mantibular bone lesions, 165
- Rabbits, myocardial infarction, isoproterenol, *tetrandrine*, histology, ECG, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- Radiation mitigators, antibiotic, antifungal agent, radiation protection, bone marrow transplant, supportive care, 9
- Radiation protection, antibiotic, antifungal agent, radiation mitigators, bone marrow transplant, supportive care, 9
- Radiation protection, antioxidant therapy, progenitor cells, gramicidin S, GS-nitroxide, esophagitis, 811
- Radical attack, oxidizing and reducing free radicals, 17 β -estradiol progesterone interaction, cyclodextrin (HBC) effect, metabolite formation, 535
- Radical attack, oxidizing and reducing free radicals, 17 β -estradiol, metabolite formation, metabolites, 173
- Radical, LEM, *Lentinus edodes* mycelia, lignin carbohydrate complex, anti-HIV, NO, macrophage, ESR, lignin-like activity, 543
- Radioguided surgery, neuroendocrine tumours, NET, gamma probe, radionuclide therapy, review, 97
- Radionuclide therapy, neuroendocrine tumours, NET, radioguided surgery, gamma probe, review, 97
- Radioprotectors, antioxidants, nitroxides, bone, 377
- RAR α , retinoic acid receptor α , acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, rexinoid acid receptor, RXR, 21
- RASSF1A*, 5-azacytidine, daidzein, genistein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *GSTPI*, *EPHB2*, *BRCA1*, soy phytoestrogens, DNA methylation, 393
- Rat retina, gene expression profile, apoptosis, oxidative stress, proton radiation, 425
- Rat, circadian rhythms, hormones, marmoset, 827
- Rat, femoral head, hip joint luxation, osteonecrosis, 821
- Rat, oestrogen, progesterone, fatty acid, mammary cancer, 553
- Rats, buprenorphine, surgery, corticosterone, behaviour, 131
- Rats, salivary gland, scintigraphy, animal model, 681
- Rb, squamous cell carcinomas, tissue microarray, immunohistochemistry, p53, p16, p21, 315
- 3D-Reconstruction of facial bone, ameloblastoma, dentigerous cyst, maxillary sinus tumor, calretinin, 567
- Reduction, animal experiments, embryos, larvae, replacement, *Xenopus*, zebrafish, CAM, early life stage models, review, 457
- Reference equations, lung volumes, pulmonary function test, childhood, 195
- Refinement, analgesia, buprenorphine, corticosterone, cerebral ischaemia, 641
- Regeneration, osteoradionecrosis, mandible, critical size defect, platelet rich plasma, 889
- Regeneration, uterus, muscle, vessels, 431

- Regulatory T lymphocytes, anticancer immunity, melatonin, pineal gland, 787
- Remote ischemic preconditioning, chronic hind limb ischemia, angiogenesis, ischemia reperfusion injury, infarct size, arteriogenesis, 147
- Renal function, ^{99m}Tc-DMSA, ^{99m}Tc-DTPA, ^{99m}Tc-MAG3, rabbit, 137
- Renewable energy, biodiesel, glycerol, gene expression, *Gadd45a*, Nfkb1, 303
- Replacement, animal experiments, embryos, larvae, reduction, *Xenopus*, zebrafish, CAM, early life stage models, review, 457
- Resveratrol, nitric oxide, peroxyxynitrite, singlet oxygen, ultraviolet C radiation, rabbit brain synaptosomes, neurotoxicity, 49
- Retinoic acid receptor α , RAR α , acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, rexinoid acid receptor, RXR, 21
- Reversal of resistance, non-antibiotics, bacteria, antibiotics, 751
- Reversibility, Wernicke-Korsakoff syndrome, alcohol abuse, thiamine deficiency, treatment, 231
- Review, alcohol abuse, personality, personality disorders, comorbidity, 761
- Review, animal experiments, embryos, larvae, replacement, reduction, *Xenopus*, zebrafish, CAM, early life stage models, 457
- Review, colon cancer immunogenicity, dendritic cell vaccine, autologous vaccine, anti-idiotypic vaccine, 607
- Review, neuroendocrine tumours, NET, radioguided surgery, gamma probe, radionuclide therapy, 97
- Review, phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, XDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, 409
- Reviews, 97, 409, 457, 607, 761, 771
- Rexinoid acid receptor, RXR, acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, retinoic acid receptor α , RAR α , 21
- RFLP, *VEGF*, polymorphism, endometriosis, 297
- Rorschach's test, anticancer immunity, psychoncology, T-regulatory lymphocytes, 75
- RXR, rexinoid acid receptor, RAR α , retinoic acid receptor α , acute myeloid leukemia, AML, acute promyelocytic leukemia, APL, all-*trans* retinoic acid, ATRA, CCAAT/enhancer binding protein epsilon, C/EBP ϵ , cell cycle arrest, differentiation, cyclin dependent-kinase 1, CDK1, cyclin dependent-kinase 2, CDK2, cyclin A1, cyclin A2, A2, PML-RAR α , promyelocyte, PM, granulocyte, promyelocytic leukemia zinc finger protein, PLZF, 21
- Saliva, aging, amino acids, glycine, 853
- Saliva, diurnal change, amino acids, student life, stress, 837
- Salivary gland, scintigraphy, animal model, rats, 681
- Sasa senanensis* Rehder extract, anti-inflammatory activity, chlorophyllin, lignin-carbohydrate complex, stomatitis, 735
- Scar management, hypertrophic scar, scar topical therapy, cyanoacrylates, silicone gel, 591
- Scar topical therapy, hypertrophic scar, scar management, cyanoacrylates, silicone gel, 591
- Schizophrenia, aneuploidy, chromosome X, GTG-banding, fluorescence *in situ* hybridization, 281
- Scintigraphy, neuroendocrine tumours, diagnosis, somatostatin, PET-DOTA peptides, short review, 771
- Scintigraphy, salivary gland, animal model, rats, 681
- Scutellariae* radix, prostaglandin E₂, structure-activity relationship, inhibition, flavone, 55
- SEM, carotid, atheromatic plaque, oxidative stress, free radicals, lipids, peroxidation, infrared, 883
- Serine, glycine, macrophage, activation, LPS, 857
- Seroma, veress needle, periprosthetic fluid, breast, haematoma, 219
- Short review, neuroendocrine tumours, diagnosis, somatostatin, scintigraphy, PET-DOTA peptides, 771
- Side-effects, breast cancer, adjuvant hormone therapy, complementary medicine, tolerability, 799
- SIL-2R, IFN- γ , IL-1 β , IL-2, IL-4, IL-6, sIL-4R, sIL-6R, sTNFR1, sTNFR2, TNF- α , immune response, 117
- SIL-4R, IFN- γ , IL-1 β , IL-2, IL-4, IL-6, sIL-2R, sIL-6R, sTNFR1, sTNFR2, TNF- α , immune response, 117
- SIL-6R, IFN- γ , IL-1 β , IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sTNFR1, sTNFR2, TNF- α , immune response, 117
- Silicone gel, hypertrophic scar, scar management, scar topical therapy, cyanoacrylates, 591
- Simultaneous neoplasm, gastrointestinal stromal tumors, GIST-other tumor association, IHC, mutation analysis, 109
- Singlet oxygen, nitric oxide, peroxyxynitrite, resveratrol, ultraviolet C radiation, rabbit brain synaptosomes, neurotoxicity, 49
- Sirolimus-eluting stents, drug-eluting stent, hemostasis, platelet activation, stent thrombosis, 635
- Somatostatin, neuroendocrine tumours, diagnosis, scintigraphy, PET-DOTA peptides, short review, 771

- Soy phytoestrogens, 5-azacytidine, daidzein, genistein, immunohisto-chemistry, methylation-specific-PCR, prostate cancer, *GSTP1*, *EPHB2*, *RASSF1A*, *BRCA1*, DNA methylation, 393
- Squamous cell carcinomas, tissue microarray, immunohistochemistry, p53, p16, p21, Rb, 315
- Standardised uptake value, positron-emission tomography, atypical neurofibroma, malignant peripheral nerve sheath tumour, neurofibromatosis type 1, podoplanin, 871
- Staphylococcus aureus*, osteomyelitis, porcine model, pig, pyaemia, 257
- Stent thrombosis, drug-eluting stent, hemostasis, platelet activation, sirolimus-eluting stents, 635
- STNFRI, IFN- γ , IL-1 β , IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRII, TNF- α , immune response, 117
- STNFRII, IFN- γ , IL-1 β , IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, TNF- α , immune response, 117
- Stomatitis, *sasa senanensis* Rehder extract, anti-inflammatory activity, chlorophyllin, lignin-carbohydrate complex, 735
- Stress, breast disease, psychosocial factors, 899
- Stress, diurnal change, saliva, amino acids, student life, 837
- Structure-activity relationship, *scutellariae* radix, prostaglandin E₂, inhibition, flavone, 55
- Student life, diurnal change, saliva, amino acids, stress, 837
- Subsets, ionizing radiation, lymphocytes, whole-body irradiation, WBI, 719
- Supportive care, antibiotic, antifungal agent, radiation protection, radiation mitigators, bone marrow transplant, 9
- Surface characteristics, titanium alloys, osteoblast, amino acid metabolism, glutamine, 29
- Surgery, buprenorphine, corticosterone, behaviour, rats, 131
- Surgery, thyroid lesions, FNAC, management, 333
- Surgical technique, pilonidal sinus, platelet gel, Vivostat™, 583
- Synchronization, chronobiology, cortisol rhythm, melatonin, pineal gland, 239
- Syngeneic, ascorbic acid, metastases, tumor, prostate, 249
- T lymphocyte, acute graft-versus-host disease, antigen presenting cells, immunosuppressive, *in vivo*, mesenchymal stem cells, 659
- T-cell receptor, oxytocin, estrogen, interleukin-2, lymphocytes, cell cycle, 157
- Tetrahymena thermophila*, MALDI-TOF, proteome, proteomics, TRI reagent, 2-D electrophoresis, peptide finder, 443
- Tetrandrine*, myocardial infarction, isoproterenol, rabbits, histology, ECG, cardiac necrosis markers, c-troponin I, myoglobin, malondialdehyde, partial thromboplastin time, 265
- TGF β ₁, uPA, uPAR, myocardial infarction, 647
- Therapy with thioridazine, phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, XDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, review, 409
- Therapy, antisense oligonucleotides, prostate cancer, 489
- Thiamine deficiency, Wernicke-Korsakoff syndrome, alcohol abuse, treatment, reversibility, 231
- Thioridazine, phenothiazines, pulmonary tuberculosis, MDR TB, XDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, review, 409
- Thoracic malignancies, PET, PET/CT, 235
- Thyroid lesions, FNAC, surgery, management, 333
- Tirapazamine, orthotopic tumors, MnSOD-PL, cetuximab, gene therapy, 1
- Tissue engineering, fetoscopy, fetal membranes, premature rupture of membranes, wound healing, amnion cells, 745
- Tissue hypoxia, carbon dioxide therapy, chronic wounds, 223
- Tissue inhibitors of matrix metalloproteinases, matrix metalloproteinases, follicular fluid, polycystic ovary syndrome, *in vitro* fertilisation, 293
- Tissue microarray, squamous cell carcinomas, immunohistochemistry, p53, p16, p21, Rb, 315
- Titanium alloys, surface characteristics, osteoblast, amino acid metabolism, glutamine, 29
- Titanium, UV irradiation, cell attachment, MTT method, amino acid consumption, osteoblastic adhesion, 519
- TNF- α , hydroxyitraconazole, itraconazole, macrophage, NO, PGE₂, IL-1 β , pro-inflammatory substances, 709
- TNF- α , IFN- γ , IL-1 β , IL-2, IL-4, IL-6, sIL-2R, sIL-4R, sIL-6R, sTNFRI, sTNFRII, immune response, 117
- TNF α , liver metastases, colorectal cancer, apoptosis, PCTS, CD95, 653
- Tolerability, breast cancer, adjuvant hormone therapy, side-effects, complementary medicine, 799
- TRAIL, vanillin, NF- κ B, apoptosis, cervical cancer, 501
- Transplantation, fertility preservation, uterus, cryopreservation, female reproductive tract, 629
- Treatment, Wernicke-Korsakoff syndrome, alcohol abuse, thiamine deficiency, reversibility, 231
- T-regulatory lymphocytes, anticancer immunity, psychoncology, Rorschach's test, 75
- Trehalose dimycolate, *mycobacterium tuberculosis*, octyl β -D-glucopyranoside, n-dodecyl β -D-maltoside, bacterial coat, pulmonary tuberculosis, 687
- TRI reagent, MALDI-TOF, proteome, proteomics, *Tetrahymena thermophila*, 2-D electrophoresis, peptide finder, 443
- Tropones, hormesis, UV protection, 843
- Tumor necrosis factor, interleukin-1 β , interleukin-6, IVF, pregnancy, 495
- Tumor, ascorbic acid, metastases, syngeneic, prostate, 249
- Tumor-specificity, 2-aminotropones, hormesis, 39
- TUNEL, adenocarcinoma of lung, FNAB, apoptosis, MIB-1, 667
- Ulnar artery thrombosis, ulnar nerve entrapment, Guyon's canal, 779

- Ulnar nerve entrapment, ulnar artery thrombosis, Guyon's canal, 779
- Ultraviolet C radiation, nitric oxide, peroxy nitrite, singlet oxygen, resveratrol, rabbit brain synaptosomes, neurotoxicity, 49
- Umbilical cord blood donation, postpartal anaemia, caesarean section, maternal blood loss, haemoglobin, 339
- UPA, TGF β ₁, uPAR, myocardial infarction, 647
- UPAR, TGF β ₁, uPA, myocardial infarction, 647
- Urinalysis, curcumin, clinical trial, GEM assay, 861
- Uterus, fertility preservation, transplantation, cryopreservation, female reproductive tract, 629
- Uterus, regeneration, muscle, vessels, 431
- UV irradiation, titanium, cell attachment, MTT method, amino acid consumption, osteoblastic adhesion, 519
- UV protection, tropones, hormesis, 843
- Vanillin, TRAIL, NF- κ B, apoptosis, cervical cancer, 501
- VEGF, polymorphism, endometriosis, RFLP, 297
- Veress needle, periprosthetic fluid, breast, seroma, haematoma, 219
- Vessels, regeneration, uterus, muscle, 431
- Vitamin D receptor, polymorphism, oral squamous cell carcinoma, 755
- Vivostat™, pilonidal sinus, platelet gel, surgical technique, 583
- Vulva, multiple endocrine neoplasia, metastasis, calcitonin, 791
- WBI, ionizing radiation, lymphocytes, subsets, whole-body irradiation, 719
- Wernicke-Korsakoff syndrome, alcohol abuse, thiamine deficiency, treatment, reversibility, 231
- Whole-body irradiation, WBI, ionizing radiation, lymphocytes, subsets, 719
- Working memory, central auditory processing disorders, fMRI, phonemic task, phonological store, dichotic listening, 201
- Wound healing, fetoscopy, fetal membranes, premature rupture of membranes, amnion cells, tissue engineering, 745
- XDR TB, phenothiazines, thioridazine, pulmonary tuberculosis, MDR TB, human macrophage, enhanced killing activity by macrophage, efflux pumps, therapy with thioridazine, review, 409
- Xenopus*, animal experiments, embryos, larvae, replacement, reduction, zebrafish, CAM, early life stage models, review, 457
- Zebrafish, animal experiments, embryos, larvae, replacement, reduction, *Xenopus*, CAM, early life stage models, review, 457

Authors Index

(Figures refer to page numbers)

- Aalbæk B, 257
 Abdel-Fattah SM, 525
 Abelson KSP, 131, 641
 Adachi K, 519, 837
 Adjakly M, 393
 Adunka O, 603
 Agachan B, 243, 297
 Agerholm JS, 257
 Agnantis NJ, 109
 Akashi T, 561
 Akita S, 853
 Akrivos N, 791
 Alamanou A, 49
 Alevizaki M, 791
 Alexandraki S, 195
 Alexandridou A, 443
 Al-Hasani S, 495
 Almeida APG, 271
 Al-Nahhas A, 97, 771
 Álvarez-Barrientes A, 431
 Amano S, 735
 Amaral L, 409, 751
 Anagnostopoulos AK, 443
 Anagnostopoulos D, 443
 Anant S, 861
 Anastassopoulou J, 883
 Antsaklis A, 791
 Apostolikas N, 109
 Ardito G, 333
 Arikani S, 179
 Armitage L, 687
 Arnogiannaki N, 109
 Arnoldner C, 603
 Arora R, 687
 Arzu EH, 65
 Asimakopoulos B, 495
 Attar E, 243, 297
 Attar R, 243, 297
 Badr El-Din NK, 525
 Baka S, 293
 Balsalobre Hernández B, 719
 Banti E, 771
 Bargellini T, 215
 Barhoumi R, 401
 Bartel-Friedrich S, 201
 Bartolacelli E, 75
 Bas F, 65
 Basso SMM, 329, 775
 Batignani G, 215
 Baumann T, 783
 Beckmann MW, 629
 Behe M, 681
 Behr TM, 681
 Bektaş-Kayhan K, 755
 Bergqvist J-E, 235
 Bergqvist M, 235
 Bergström S, 235
 Bernard M, 811
 Bernard-Gallon DJ, 393
 Bertani S, 827
 Bertoglio S, 889
 Beuth J, 227, 799
 Beyer ME, 635
 Bhogal N, 457
 Biemer E, 745
 Bignon Y-J, 393
 Biliatis I, 791
 Blackburn MR, 687
 Bochnia M, 165
 Boiteux J-P, 393
 Borggreffe M, 189, 635
 Boschian A, 641
 Bosviel R, 393
 Boufidou F, 325
 Bradlow HL, 387
 Brafa A, 223
 Brandi C, 223
 Brenna S, 265
 Brivio F, 239, 787
 Brivio R, 239
 Broecker Y, 201
 Brossart P, 45
 Burbano RMR, 281, 579
 Bürk J, 783
 Cacina C, 179, 243
 Cafiero F, 889
 Caggiati A, 575
 Calabrò M, 223
 Campa A, 223
 Campana M, 223
 Campanella A, 575
 Carboni L, 827
 Carlesimo B, 219
 Carughi S, 471
 Carvalho S, 271
 Cegielski M, 165
 Chae HI, 137
 Chatzipanagiotou S, 325
 Chen J-C, 287
 Chessa P, 157
 Chiara GB, 329, 775
 Chiba H, 55
 Chiba Y, 561
 Chiummariello S, 591
 Choi SH, 137, 821
 Chondrogiannis S, 771
 Chrelias C, 117
 Chu Q, 735
 Chung J-G, 287
 Cioppa T, 79
 Clerici M, 75
 Cogliandro A, 575
 Colombo E, 75
 Contreras RG, 507, 513, 519
 Coronado MJ, 431
 Corvò R, 889
 Couto I, 409
 Creatsas G, 293
 Criado A, 827
 D'Alessandro M, 79
 D'Amico S, 79
 D'Aniello C, 223
 Danielova I, 535, 727
 Darendeliler F, 65
 Dastidar S, 409
 De Arruda Cardoso Smith M, 281
 De Cata A, 471
 De Hauwere L, 865
 De Lima PD, 281
 De Marco G, 79
 De Moraes LS, 281
 De Simone M, 79
 Dechelotte P, 393
 Deliconstantinos G, 49
 Demeridou S, 293
 Demirel C, 495
 Dempfle C-E, 189, 635
 Derlin T, 871
 Dessouki A, 401
 Dessy LA, 219, 591
 Di Fede G, 239, 787
 Diamantis A, 667
 Dick Jr EJ, 705
 Diedrich K, 495
 Diensthuber M, 603
 Dimitriadis E, 109
 Dittrich R, 629
 Dixon T, 1, 377, 811
 Do Nascimento Borges B, 579
 Dritsa V, 883
 Dzięgiel P, 165
 Dziejwiczek W, 165
 Eckert K, 59
 Eftihios T, 117
 Eichelbaum EJ, 125
 Eidelman O, 249
 Eiró N, 431
 Eivazi B, 681
 Ekman S, 235
 El-Meligy A, 401
 Ember I, 303
 Epperly MW, 1, 9, 377, 811
 Ergen HA, 755
 Eskelinen M, 899
 Fadda G, 333
 Fafouti M, 803
 Fanning S, 409
 Fanti G, 329, 775
 Faueryby N, 641
 Felberbaum R, 495
 Fetaih H, 401
 Fettich J, 97, 771
 Fichtner I, 59
 Fida A, 109
 Fiorentini G, 79
 Fontana L, 393
 Fotiou D, 49
 Fotiou S, 49
 Fracalossi ACC, 315
 Franco MF, 315
 Franicola D, 1, 9, 811
 Friedrich RE, 211, 567, 571, 871, 877, 895
 Fuhrmann A, 895
 Fujiki M, 671
 Fumagalli G, 239
 Fumagalli L, 239, 787
 Furuya Y, 561
 Fuse H, 561
 Galmozzi G, 265
 Gálvez BG, 431
 Gao X, 811
 Gazalidou M, 109
 Georges G, 9

- Gerlach U, 783
 Gerschpacher M, 173, 535, 727
 Getoff N, 173, 535, 727
 Ghoneum A, 141
 Ghoneum M, 141, 525
 Giannikaki E, 667
 Giannini G, 583
 Gimzewski J, 141
 Gipponi M, 583, 889
 Giustozzi E, 333
 Glava I, 147
 Glowacki J, 377
 Goff JP, 377, 811
 Gokhale A, 377
 Goldkuhl R, 131
 Gombos K, 303
 Gomes TS, 315
 Gorschlüter M, 45
 Govind J, 861
 Greco A, 471
 Green LM, 425
 Greenberger JS, 1, 9, 377, 811
 Gridley DS, 425
 Grimaldi L, 223
 Grzyska U, 877
 Gstöttner W, 603
 Guinan P, 489
 Guo Z, 659
 Guy L, 393
 Hafiz G, 755
 Hagel C, 871
 Halapas A, 647
 Hamazaki K, 553, 561
 Hamazaki T, 553, 561
 Hambek M, 603
 Han TS, 821
 Harada ML, 579
 Harnack U, 59
 Hartmann J, 173, 535, 727
 Hashimoto K, 55, 709, 843
 Hassiakos D, 293
 Hau J, 131, 641
 Helbig K, 339
 Henke J, 745
 Hernández-Godoy J, 719
 Hes O, 699
 Hibino Y, 29, 507, 519
 Higashihara E, 561
 Hodolič M, 97, 771
 Hoeffken H, 681
 Hoffmann I, 629
 Hoffmeister HM, 189, 635
 Holgersson G, 235
 Hondequin J, 865
 Horch RE, 745
 Horie N, 55, 709
 Horiuchi M, 671
 Houchen CW, 861
 Huber JC, 173, 535, 727
 Ibrahim A, 401
 Iburg T, 257
 Iliodromitis EK, 147
 Ilvan Ş, 71
 Inglese M, 471
 Inokuchi Y, 671
 Isbir T, 65, 71, 179, 243, 297, 755
 Itomura M, 561
 Izumi Y, 671
 Iżykowska I, 165
 Jahn L, 257
 Jensen HE, 257
 Jeschke U, 695
 Jiang X, 659
 Johannesen TB, 85
 Johannesson E, 257
 Johansen FF, 641
 Johansen LK, 257
 Jønsson V, 85
 Kagan V, 811
 Kaklamanis L, 147
 Kalliokoski O, 641
 Kalogeraki A, 667
 Kalykaki M, 325
 Kameyama S, 561
 Kanai AJ, 1
 Kanamoto T, 543, 735
 Kanavakis E, 309
 Kanczuga-Koda L, 101
 Kaneko T, 55, 709
 Kanematsu S, 553
 Kang SS, 137, 821
 Kantoh K, 843
 Kapsambeli H, 117
 Karadeniz A, 755
 Karaiskos D, 231, 325
 Kasper H-U, 653
 Kassanos D, 117
 Kato T, 55, 709
 Katsardis C, 195
 Katz A, 607
 Käufl SD, 695
 Kawa G, 561
 Kawaguchi H, 463, 671
 Kawakita M, 561
 Kawanaka A, 553
 Kawano M, 543, 735
 Kehl S, 339
 Kern M, 653
 Khayat AS, 281
 Kim G, 821
 Kim J-H, 137
 Kim JM, 137, 821
 Kim Y, 45
 Kisakesen HI, 71
 Kitajima M, 735
 Kitsiou-Tzeli S, 309
 Knoergen M, 201
 Kobayashi M, 29, 55
 Kobr J, 641, 699
 Kocova J, 699
 Koda M, 101
 Kodama H, 837
 Koesling S, 201
 Koizumi K, 501
 König A, 321
 Konze E, 653
 Kos D, 865
 Köster F, 495
 Kotileas P, 883
 Kountourakis P, 109
 Kouskouni E, 293
 Koutsilieris M, 195, 647
 Kouzoupis A, 231
 Kovács A, 303
 Kovacs L, 745
 Kremastinos DT, 147
 Kristiansen JE, 409, 751
 Krueger GR, 687
 Kuhn C, 695
 Kuntscher V, 699
 Kunze S, 695
 Kuran SB, 243, 297
 Kuroshita R, 735
 Kuryszko J, 165
 Kusama K, 55, 709
 Kuwata M, 553
 Kyriakides ZS, 147
 Kyriakidis DI, 745
 Lai SY, 1
 Lai T-Y, 287
 Lai Y-C, 553
 Lamelas ML, 431
 Langer M, 783
 Lazcano JJ, 431
 Leal MF, 281
 Lee WG, 137
 Leifsson PS, 257
 Lenz A, 125
 Levine MA, 249
 Leze E, 309
 Li H, 659
 Li S, 811
 Li XS, 659
 Liao L, 659
 Liappas A, 325
 Liappas I, 231, 325, 761, 803
 Librizzi D, 681
 Lima EM, 281
 Lindsey N, 425
 Lioe Ko H, 227
 Lirdprapamongkol K, 501
 Lissoni P, 75, 157, 239, 787
 Liu Y, 659
 Lopresi B, 1
 Lu K-W, 287
 Lu P-J, 287
 Lumachi F, 329, 775
 Ly B, 85
 Lyras T, 147
 Ma Y-S, 287
 Macciò A, 157
 Machens H-G, 745
 Machino M, 735, 853
 Madeddu C, 157
 Magotti L, 75
 Makino T, 543
 Makovitzky J, 695
 Makrakis E, 293
 Makrythanasis P, 309
 Malamos N, 803
 Maltaris T, 629
 Mamarelis I, 883
 Mangiarini L, 827
 Mantovani G, 157
 Mao N, 659
 Mao XW, 425
 Marchetti Federico, 219
 Marchetti Francesco, 219
 Marchiori P, 75
 Martín NS, 431
 Martins A, 409, 751
 Martins M, 409
 Martzoukou I, 109
 Marzano B, 329, 775
 Marzola MC, 97, 333
 Mason N, 1
 Massa M, 889
 Matsuda T, 561
 Matsumoto A, 795

- Mazza F, 329, 775
Mazzocchi M, 219, 591
Mazzoccoli G, 471
McBride W, 9
McCusker M, 409
Meeus M, 865
Mekonnen T, 425
Mellios T, 227
Mellos E, 761
Mereu P, 889
Merika E, 607
Messina G, 75, 787
Michalopoulou M, 325
Michielin F, 827
Mikhailidis DP, 147
Misumi K, 671
Mito Y, 795
Miura N, 671
Miyajima H, 671
Miyamoto Y, 463, 671
Miyoshi N, 463, 671
Mohri K, 735
Molacek J, 699
Møller M, 257
Molnar J, 409
Monacelli G, 779
Monarca C, 779
Mondalek FG, 861
Morse M, 607
Moschella F, 333
Mueller A, 629
Müller F, 681
Munk L, 257
Muraglia A, 889
Murota T, 561
Myhr K-M, 185
Mylonas I, 695
Naess H, 185
Nagata R, 671
Nakajima H, 29, 507, 513, 519
Nakamura Yuki, 837
Nakamura Yukio, 507, 843
Nakamura Yuko, 507, 843
Nakashima H, 543, 735
Narita T, 39
Nascimento FD, 315
Nastoulis E, 109
Nesi G, 215
Nicolau C, 325
Nielsen OL, 257
Nijs J, 865
Nikolettos N, 495
Nishiyama A, 857
Nisi G, 223
Niu Y, 1
Noaman E, 525
Nyland HI, 185
Oikawa O, 795
Oizumi H, 735
Oizumi T, 735
Okegawa T, 561
Ollonen P, 899
Olsen JH, 85
Onesti MG, 591
Ono M, 843
Onuki H, 29
Oppelt PG, 629
Orrego A, 705
Oshima CTF, 315
Owston M, 705
Öztürk O, 71
Öztürk T, 71
Pages J-M, 409
Panani AD, 715
Pantazis P, 861
Panzone F, 157
Papadakis M, 667
Papadopulos NA, 745
Papanikolaou NA, 21
Paparrigopoulos T, 231, 325, 761, 803
Papathanasaki A, 109
Paraskevas KI, 147
Park J, 821
Patrene K, 377
Pecher G, 59
Perfetto F, 471
Persichetti P, 575
Pescia S, 239
Petraiki PE, 667
Petri E, 339
Pfestroff A, 681
Philippou A, 647
Pi G, 125
Pinelli A, 265
Pinto GR, 281
Pissaridi K, 883
Pissimissis N, 647
Pizingerova K, 699
Planelles Silvestre D, 719
Pollard HB, 249
Pollard M, 249
Ponnurangam S, 861
Potenza C, 575
Prangsaengtong O, 501
Protonotariou E, 117
Quint R-M, 173, 727
Rabavilas A, 803
Rabiau N, 393
Ralha D, 271
Ramanujam RP, 861
Ramos J, 409
Rasmussen RS, 641
Reboa G, 583
Revelli L, 333
Rey KS, 635
Ribeiro DA, 315
Riedl N, 603
Risin SA, 687
Rizzo MI, 779
Rodolakis A, 791
Rodrigues L, 409
Rodríguez C, 431
Rogelio J, 507
Rossi ED, 333
Rossoni G, 265
Rovelli F, 239, 787
Rubello D, 97, 333, 771
Rubenstein M, 489
Rubio CA, 599, 705
Ruchirawat S, 501
Rwigema J-C, 9, 377, 811
Saglam EK, 179
Saif MW, 607
Saiki I, 501
Sakagami H, 29, 39, 55, 507, 513, 519, 543, 709, 735, 837, 843, 853, 857
Sakurai H, 501
Salama-Cohen P, 431
Santi P, 889
Sarandakou A, 117
Satih S, 393
Satoh K, 543, 709, 837
Scala M, 889
Scaringi S, 215
Scheuer HA, 877, 895
Schillinger U, 745
Schittl H, 173, 535, 727
Schmidt-Wolf IGH, 45
Schneider B, 799
Schneider KTM, 745
Scuderi N, 591, 779
Seabra R, 457
Sekine K, 735
Shen H, 811
Shields D, 9
Shim KM, 137
Shimada J, 29, 507, 513, 519
Shimoyama T, 709
Shioda S, 543
Shirataki Y, 735
Siafaka-Kapadai A, 443
Siafakas N, 195, 667
Siemer J, 339
Sievers E, 45
Skampardonis N, 791
Skelton IV WP, 125
Song L, 687
Sotiropoulou M, 791
Souda M, 463
Sourla A, 647
Sozen S, 243
Spagnoli AM, 779
Spartinos J, 147
Spengler G, 409
Spyrou G, 443
Stathopoulos E, 667
Stavropoulou A, 647
Stenström M, 235
Stippel DL, 653
Stoica G, 401
Stone B, 9
Stoops JK, 687
Stöver T, 603
Strada P, 583, 889
Strahl O, 629
Strehl JW, 45
Subramaniam D, 861
Sudo K, 795
Suga A, 39
Sulkowska M, 101
Sulkowski S, 101
Sun Y, 125
Sundal E, 185
Suselbeck T, 189, 635
Sutradhar BC, 821
Sütterlin M, 339
Suzuki S, 501
Svasti J, 501
Swoboda S, 189, 635
Syrigos K, 607
Szabo S, 635
Szele E, 303
Szendi K, 153
Tajima Y, 795
Takada H, 553, 561
Takeuchi T, 671
Tamiolakis D, 667
Tanaka S, 735, 853
Tang N-Y, 287

- Tanimoto A, 671
 Tarquini R, 471
 Tashiro K, 795
 Tenna S, 575
 Terachi T, 561
 Terakubo S, 735
 Terakubu S, 543
 Testa T, 583
 Teymoortash A, 681
 Thet MM, 735
 Thomakos N, 791
 Thomsen VF, 751
 Thormose SF, 641
 Timirci O, 65
 Tjønnfjord GE, 85
 Tokunaga M, 561
 Tokunaga S, 671
 Tolentino L, 141
 Tomás AM, 271
 Tonelli F, 215
 Tonini E, 97
 Topolcan O, 699
 Toptaş B, 297, 755
 Totis A, 745
 Toubarro DN, 271
 Trivulzio S, 265
 Tsangaris GT, 443
 Tsiligiris V, 883
 Tsubura A, 553
 Tüzüner BM, 71
 Tzanakaki D, 293
 Tzardi M, 667
 Tzavara C, 803
 Tzavellas E, 231, 325
 Tzilalis V, 883
 Uesawa Y, 735
 Uhlenbruck G, 799
 Umekita Y, 463
 Umit Z, 65
 Ünür M, 755
 Vaira M, 79
 Van Eupen I, 865
 Van Leendert R, 799
 Vardi A, 393
 Varga C, 153
 Varnavas VC, 147
 Vesely DL, 125
 Vicentini E, 827
 Vigorè L, 787
 Vilchis S, 507
 Viriyaraj A, 501
 Viveiros M, 409, 751
 Vizoso F, 431
 Von Loga K, 321
 Vougas K, 443
 Vrettou C, 309
 Waczek S, 495
 Wagenblast J, 603
 Wakabayashi H, 39, 843
 Walter T, 189, 635
 Wang H, 377, 811
 Wang Q-T, 735
 Wang X, 659
 Wanger A, 687
 Watanabe S, 735, 837
 Wendel HP, 635
 Weng J-R, 287
 Weng S-W, 287
 Willems P, 309
 Wilson WR, 1
 Wincewicz A, 101
 Winterer JT, 783
 Wipf P, 9, 377, 811
 Wu Y, 659
 Xanthopoulou AG, 443
 Yang J-S, 287
 Yao H, 659
 Yasuda N, 463, 671
 Yaylim Eraltan I, 179, 297,
 755
 Ying S, 535, 727
 Yokote Y, 29, 519, 837, 853,
 857
 Yoshida H, 463, 671
 Yoshizawa K, 553
 Yuille M, 85
 Yurdum LM, 243
 Zabel M, 165
 Zaiss I, 339
 Zalewski B, 101
 Zatoński M, 165
 Zeligs MA, 387
 Zerrin C, 71
 Zervas Y, 803
 Zeybek U, 179
 Zhang C-H, 735
 Zhang X, 9
 Zhang Y, 659
 Zhou L, 735
 Zhu H, 659
 Zoga A, 147
 Zoga M, 325
 Zoras O, 667
 Zourla K, 293
 Zustin J, 211, 321, 567, 571,
 877, 895

Errata

Volume 23: 1 (2009), page 21: seventh author should read:

YUE-FENG YANG

Volume 24: 5 (2010), page 607: fourth author should read:

K. SYRIGOS

Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form.

All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: <http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org (mail to: journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO and CANCER GENOMICS & PROTEOMICS
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

online from January 2009



in vivo

International Journal of Experimental and Clinical Pathophysiology and Drug Research

PRINT ISSN: 0258-851X, ONLINE ISSN: 1791-7549

General Policy: IN VIVO is an international peer reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frame of comparative physiology and pathology. Articles are drawn from scientific areas including oncology, pharmacology, chemotherapy, bioterapy, immunology, radiology, toxicology, genetics, cytology, endocrinology, nutrition, comparative pathology, development, biotechnology. Special focus of the journal is the publication of works on: (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models of biomedical research. The principle aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports (a) the aims and research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Publication Data: IN VIVO is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in IN VIVO, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Annual Subscription Rates 2011: Institutional, print: Euro 875.00, online: Euro 855.00, print & online: Euro 890.00; Personal, print: Euro 472.00, online: Euro 452.00 print & online: Euro 490.00. Prices include rapid delivery, insurance. Previous volumes of IN VIVO (Vol. 1-24, 1987-2010) are available at 50% discount on the above rates.

IN VIVO is also published online with Stanford University HighWire Press from the January 2009 issue with access to full text/PDF articles from all previous volumes since January 1st, 2004. For 2011 online/print subscription information, please visit the IN VIVO-IIAR website www.iiar-anticancer.org or www.iv.iiarjournals.org

Subscription orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Checks should be made payable to

J.G. Delinassios, Athens, Greece. In Japan, contact Woodbell Scope, Inc., 4-22-11, Kitakassai, Edogawa-ku, Tokyo 134, Japan.

Articles in IN VIVO are regularly indexed in bibliographic services, including PubMed, Index Medicus, MEDLINE, Biological Abstracts, BIOSIS, Chemical Abstracts, Excerpta Medica, CANCER-LIT Database, University of Sheffield Biomedical Information Service (SUBIS), Current Clinical Cancer, AIDS Abstracts, Progress in Palliative Care, Update-Research Information Systems Inc., Inpharma-Reactions Datarstar, BRS, Reference Update (I.S.I.), Research Alert (I.S.I.), BioBase, MedBase, Investigational Drugs Database, VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Databases.

The Editors and Publisher of the journal IN VIVO accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by IN VIVO, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0258-851 X 2011 \$2.00 + .40.

Correspondence (subscription orders, reprint orders, disposition of submitted manuscripts, change of address, general editorial matters, advertising rate requests) should be addressed to: Dr. J.G. Delinassios, Managing Editor.

Editorial Office: International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389.

E-mails:

Editorial Office: journals@iiar-anticancer.org

Managing Editor: editor@iiar-anticancer.org

For more information about IN VIVO and the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, please visit the IIAR website: www.iiar-anticancer.org; www.iv.iiarjournals.org